Biomarkers for prostate cancer metastasis

ABSTRACT

The present invention provides genomic markers for determining the predisposition of prostate cancer to become metastasized.

CROSS REFERENCE TO RELATED PATENT APPLICATIONS

The present patent application claims benefit of priority to U.S.Provisional Patent Application No. 60/625,399, filed on Nov. 5, 2004,which is incorporated by reference for all purposes.

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSOREDRESEARCH OR DEVELOPMENT

This invention was made with Government support under Grant No. CA89520,awarded by the National Institutes of Health. The Government has certainrights in this invention.

BACKGROUND OF THE INVENTION

Prostate cancer is the most commonly diagnosed non-cutaneous neoplasmamong males in Western countries and is estimated to result in 28,900deaths this year in the U.S. alone. The advent of widespread PSAscreening has resulted in increased detection of prostate cancer atearlier stages. A persistent and recalcitrant problem is that men withsimilar stage tumors often exhibit markedly different clinical outcomesfollowing therapy, i.e. surgery or radiation. Early detection combinedwith slowly progressing tumors means a significant subset of men may becandidates for watchful waiting or active surveillance rather thantreatment, and this will become increasingly important as the populationages. Thus, it is imperative that new methods be developed for patientstratification based on risk of recurrence to enable appropriate patientmanagement.

BRIEF SUMMARY OF THE INVENTION

The present invention provides for methods for determining the risk ofmetastasis of cancer in an individual who has or had prostate cancer. Insome embodiments, the methods comprise detecting in a tumor sample fromthe individual the number of copies per cell of genomic DNA at at leastone genomic location selected from the group consisting of 2qtel,3q26.2, 3q26.32, 5p15.1, 7p22.3, 7q11.23, 7q11.22, 7q22.1, 7q31.31,9q34.11, 11p15.5, 17q21.33, 17q25.3, 22q13.1, 4p13, 5q13.1, 5q14.3,5q21.1, 5q21.2, 5q21.3, 5q23.1, 6q14.1, 6q21, 8p22, 8p21.2, 8p12,10q23.31, 13q14.11, 13q14.13, 13q14.2, 13q14 and 16q23.1, wherein anincrease in the number of copies per cell of DNA in genomic locationsselected from the group consisting of 2qtel, 3q26.2, 3q26.32, 5p15.1,7p22.3, 7q11.23, 7q11.22, 7q22.1, 7q31.31, 9q34.11, 11p15.5, 17q21.33,17q25.3 and 22q13.1 and/or a decrease in the number of copies per cellof DNA in genomic locations selected from the group consisting of 4p13,5q13.1, 5q14.3, 5q21.1, 5q21.2, 5q21.3, 5q23.1, 6q14.1, 6q21, 8p22,8p21.2, 8 p12, 10q23.31, 13q14.11, 13q14.13, 13q14.2, 13q14 and 16q23.1,compared to the number of copies per cell in non-cancer cells, indicatesan increased risk of metastasis.

In some embodiments, the number of copies per cell of at least one ofthe above genomic regions and the number of copies per cell of 8p23.2and/or 11q13.1 are determined.

In some embodiments, the methods comprise detecting the number of copiesper cell at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 of thegenomic locations. In some embodiments, the methods comprise detectingthe number of copies per cell at 2qtel, 3q26.2, 3q26.32, 5p15.1, 7p22.3,7q11.23, 7q11.22, 7q22.1, 7q31.31, 9q34.11, 11p15.5, 17q21.33, 17q25.3,22q13.1, 4p13, 5q13.1, 5q14.3, 5q21.1, 5q21.2, 5q21.3, 5q23.1, 6q14.1,6q21, 8p22, 8p21.2, 8p12, 10q23.31, 13q14.11, 13q14.13, 13q14.2, 13q14and 16q23.1. In some embodiments, the methods comprise also detectingthe number of copies per cell of MEN1 and/or CSMD1.

In some embodiments, the methods comprise detecting the number of copiesof genomic DNA that hybridizes to at least one BAC selected from thegroup consisting of CTB-172113, RP11-1146E5, RP11-114M1, RP1-97B16,RP11-88L18, RP11-23D23, CTC-329F6, RP1-117G9, RP11-96O16, RP11-213E22,CTD-2041G23, RP11-17O4, RP4-693L23, RP5-1071I14, RP11-46E14, RMC22P003,RP11-25305, RP11-267K19, RP11-135F5, RP11-203J7, RP11-115L24,CTD-2079J2, RP11-73N22, RP11-217L13, RP11-28L24, RP11-47E20, RP11-182G2,RP11-76B12, RP11-232J22, CTD-2015D3, RP11-5713, RP11-129G17, RP11-14A4,CTD-2202J2, RP11-17I11, RP11-217H23, CTD-2173J2, RP1-269F22, andRP11-12H11.

In some embodiments, the methods comprise detecting the number of copiesof genomic DNA in a gene encoding a polypeptide selected from the groupconsisting of EV11, PIK3CA, EIF3S9, ELN, AUTS2, VGF, Serpine1, PLOD3,AP1S1, CORTBP2, p57 (KIP2), NGFR, CBX4, CBX8, PDGFB, FER, TUBE1, LAMA4,BVES, POPDC3, TUSC3, DOCK5, BNIP3L, ADRA1, NRG1, LHFP, GTF2F2, RB1 andCHC1L.

Alternatively, expression of RNA or protein encoded by theabove-described genes is used to determine the risk of metastasis in anindividual who has or had prostate cancer.

In some embodiments, at least one of the above-described genes (alsolisted in Table 2) and the number of copies per cell of MEN1 and/orCSMD1 are determined. In some embodiments, expression of RNA or proteinencoded by MEN1 or CSMD1 and expression of RNA or protein encoded by atleast one polynucleotide encoding a polypeptide selected from the groupconsisting of EV11, PIK3CA, EIF3S9, ELN, AUTS2, VGF, Serpine1, PLOD3,AP1S1, CORTBP2, p57 (KIP2), NGFR, CBX4, CBX8, PDGFB, FER, TUBE1, LAMA4,BVES, POPDC3, TUSC3, DOCK5, BNIP3L, ADRA1, NRG1, LHFP, GTF2F2, RB1 andCHC1L are detected.

The present invention also provides methods of determining the stage ofa prostate cancer tumor. In some embodiments, the methods comprisedetecting in a tumor sample from the individual the quantity of a 8p23.2polynucleotide, wherein an individual with an advanced stage of prostatecancer has fewer genomic copies of 8p23.2 per cell than a normalindividual. In some embodiments, the methods comprise detecting in atumor sample from the individual the quantity of a CSMD1 polynucleotideor polypeptide, wherein an individual with an advanced stage of prostatecancer has fewer genomic copies of CSMD1 per cell or reduced expressionof a CSMD1 mRNA, or reduced expression of a CSDM1 polypeptide than anormal individual.

In some embodiments, the CSMD1 polynucleotide is genomic DNA and adecreased number of copies per cell of the genomic DNA is associatedwith an advanced stage of prostate cancer. In some embodiments, theCSMD1 polynucleotide is a CSMD1 mRNA or cDNA thereof and decreasedexpression of the polynucleotide is associated with an advanced stage ofprostate cancer.

The present invention also provides methods of assessing the risk ofpost-prostatectomy reoccurrence of cancer in an individual. In someembodiments, the methods comprise detecting in a tumor sample from theindividual the quantity of a 11q13.1polynucleotide, wherein anindividual with a risk of post-prostatectomy reoccurrence of cancer hasan increased number of genomic copies of 11q13.1 per cell than a normalindividual. In some embodiments, the methods comprise detecting in atumor sample from the individual the quantity of a MEN1 polynucleotideor MEN1 polypeptide, wherein an individual with a risk ofpost-prostatectomy reoccurrence of cancer has an increased number ofgenomic copies of MEN1 per cell, or increased expression of a MEN1 mRNA,or increased expression of a MEN1 polypeptide, than a normal individual.In some embodiments, the methods further comprise detecting apolynucleotide or polypeptide set forth in Table 2.

In some embodiments, the MEN1 polynucleotide is genomic DNA and anincreased number of copies per cell of the genomic DNA is associatedwith a risk of post-prostatectomy reoccurrence of cancer. In someembodiments, the MEN1 polynucleotide is a MEN1 mRNA or cDNA thereof andincreased expression of the polynucleotide is associated with a risk ofpost-prostatectomy reoccurrence of cancer. In some embodiments, themethods further comprise detecting a polynucleotide or polypeptide setforth in Table 2.

The present invention also provides methods of identifying an agent thatinhibits prostate cancer proliferation or metastasis. In someembodiments, the methods comprise: contacting a plurality of agents to acell expressing a polypeptide selected from the group consisting of thegene products listed in Table 2; selecting an agent that modulatesexpression or activity of the polypeptide (i.e., directly affectspolypeptide expression or affects expression indirectly, e.g., bychanging transcript accumulation, etc.); and determining whether theselected agent inhibits prostate cancer proliferation or metastasis,thereby identifying an agent that inhibits prostate cancer proliferationor metastasis. The present invention also provides agents selectedaccording to the above method.

The present invention also provides methods of treating prostate canceror inhibiting metastasis of prostate cancer. In some embodiments, themethods comprise administrating to an individual in need thereof anagent selected according to the above method.

DEFINITIONS

The terms “tumor” or “cancer” in an animal (e.g., a human) refers to thepresence of cells possessing characteristics such as atypical growth ormorphology, including uncontrolled proliferation, immortality,metastatic potential, rapid growth and proliferation rate, and certaincharacteristic morphological features. Often, cancer cells will be inthe form of a tumor, but such cells may also exist in isolation from oneanother within an animal. “Tumor” includes both benign and malignantneoplasms.

The terms “hybridizing specifically to”, “specific hybridization”, and“selectively hybridize to,” as used herein refer to the binding,duplexing, or hybridizing of a nucleic acid molecule preferentially to aparticular nucleotide sequence under stringent conditions. The term“stringent conditions” refers to conditions under which a probe willhybridize preferentially to its target subsequence, and to a lesserextent to, or not at all to, other sequences in a mixed population(e.g., a cell lysate or DNA preparation from a tissue biopy) A“stringent hybridization” and “stringent hybridization wash conditions”in the context of nucleic acid hybridization (e.g., as in array,Southern or nrthern hybridizations) are sequence dependent, and aredifferent under different environmental parameters. An extensive guideto the hybridization of nucleic acids is found in, e.g., Tijssen (1993)Laboratory Techniques in Biochemistry and MolecularBiology—Hybridization with Nucleic Acid Probes part I, Ch. 2, “Overviewof principles of hybridization and the strategy of nucleic acid probeassays,” Elsevier, N.Y. (“Tijssen”). Generally, highly stringenthybridization and wash conditions are selected to be about 5° C. lowerthan the thermal melting point (T_(m)) for the specific sequence at adefined ionic strength and pH. The T_(m) is the temperature (underdefined ionic strength and pH) at which 50% of the target sequencehybridizes to a perfectly matched probe. Very stringent conditions areselected to be equal to the T_(m) for a particular probe. An example ofstringent hybridization conditions for hybridization of complementarynucleic acids which have more than 100 complementary residues on anarray or on a filter in a Southern or northern blot is 42° C. usingstandard hybridization solutions (see, e.g., Sambrook and Russell (2001)Molecular Cloning: A Laboratory Manual (3rd ed.) Vol. 1-3, Cold SpringHarbor Laboratory, Cold Spring Harbor Press, NY, and detaileddiscussion, below), with the hybridization being carried out overnight.An example of highly stringent wash conditions is 0.15 M NaCl at 72° C.for about 15 minutes. An example of stringent wash conditions is a0.2×SSC wash at 65° C. for 15 minutes (see, e.g., Sambrook supra. for adescription of SSC buffer). Often, a high stringency wash is preceded bya low stringency wash to remove background probe signal. An examplemedium stringency wash for a duplex of, e.g., more than 100 nucleotides,is 1×SSC at 45° C. for 15 minutes. An example of a low stringency washfor a duplex of, e.g., more than 100 nucleotides, is 4× to 6×SSC at 40°C. for 15 minutes.

A “promoter” is defined as an array of nucleic acid control sequencesthat direct transcription of a nucleic acid. As used herein, a promoterincludes necessary nucleic acid sequences near the start site oftranscription, such as, in the case of a polymerase II type promoter, aTATA element. A promoter also optionally includes distal enhancer orrepressor elements, which can be located as much as several thousandbase pairs from the start site of transcription.

The term “nucleic acid” or “polynucleotide” as used herein refers to adeoxyribonucleotide or ribonucleotide in either single- ordouble-stranded form. The term encompasses nucleic acids containingknown analogues of natural nucleotides which have similar or improvedbinding properties, for the purposes desired, as the reference nucleicacid. The term also includes nucleic acids which are metabolized in amanner similar to naturally occurring nucleotides or at rates that areimproved for the purposes desired. The term also encompassesnucleic-acid-like structures with synthetic backbones. DNA backboneanalogues provided by the invention include phosphodiester,phosphorothioate, phosphorodithioate, methylphosphonate,phosphoramidate, alkyl phosphotriester, sulfamate, 3′-thioacetal,methylene(methylimino), 3′-N-carbamate, morpholino carbamate, andpeptide nucleic acids (PNAs); see Oligonucleotides and Analogues, aPractical Approach, edited by F. Eckstein, IRL Press at OxfordUniversity Press (1991); Antisense Strategies, Annals of the New YorkAcademy of Sciences, Volume 600, Eds. Baserga and Denhardt (NYAS 1992);Milligan (1993) J. Med. Chem. 36:1923-1937; Antisense Research andApplications (1993, CRC Press). PNAs contain non-ionic backbones, suchas N-(2-aminoethyl) glycine units. Phosphorothioate linkages aredescribed in WO 97/03211; WO 96/39154; Mata (1997) Toxicol. Appl.Pharmacol. 144:189-197. Other synthetic backbones encompassed by theterm include methyl-phosphonate linkages or alternatingmethylphosphonate and phosphodiester linkages (Strauss-Soukup (1997)Biochemistry 36: 8692-8698), and benzylphosphonate linkages (Samstag(1996) Antisense Nucleic Acid Drug Dev 6: 153-156).

The term “nucleic acid array” as used herein is a plurality of targetelements, each target element comprising one or more nucleic acidmolecules (probes) immobilized on one or more solid surfaces to whichsample nucleic acids can be hybridized. The nucleic acids of a probe cancontain sequence(s) from specific genes or clones, e.g. from specificgenomic regions described in Table 2 or comprising the 8p23.2 (e.g.,CSMD1) or 11q13.1 (e.g., MEN1) locus. Other probes may contain, forinstance, reference sequences. The probes of the arrays may be arrangedon the solid surface at different densities. The probe densities willdepend upon a number of factors, such as the nature of the label, thesolid support, and the like. One of skill will recognize that each probemay comprise a mixture of nucleic acids of different lengths andsequences. Thus, for example, a probe may contain more than one copy ofa cloned piece of DNA or RNA, and each copy may be broken into fragmentsof different lengths. The length and complexity of the nucleic acidfixed onto the target element is not critical to the invention. One ofskill can adjust these factors to provide optimum hybridization andsignal production for a given hybridization procedure, and to providethe required resolution among different genes or genomic locations.

The term “probe” or “nucleic acid probe”, as used herein, is defined tobe one or more nucleic acid fragments whose specific hybridization to asample can be detected. The probe may be unlabeled or labeled asdescribed below so that its binding to the target or sample can bedetected. The probe is produced from a source of nucleic acids from oneor more particular (preselected) portions of a chromosome, e.g., one ormore clones, an isolated whole chromosome or chromosome fragment, or acollection of polymerase chain reaction (PCR) amplification products.The probes of the present invention are produced from nucleic acidsfound in the regions described herein. Often, the probes are centromericprobes, i.e., they hybridize to nucleic acid sequences present in thecentromeres of the specific chromosomes, which provide a strongersignal.

The probe may also be isolated nucleic acids immobilized on a solidsurface (e.g., nitrocellulose, glass, quartz, fused silica slides), asin an array. In some embodiments, the probe may be a member of an arrayof nucleic acids as described, for instance, in WO 96/17958. Techniquescapable of producing high density arrays can also be used for thispurpose (see, e.g., Fodor (1991) Science 767-773; Johnston (1998) Curr.Biol. 8: R171-R174; Schummer (1997) Biotechniques 23: 1087-1092; Kern(1997) Biotechniques 23: 120-124; U.S. Pat. No. 5,143,854). One of skillwill recognize that the precise sequence of the particular probesdescribed herein can be modified to a certain degree to produce probesthat are “substantially identical” to the disclosed probes, but retainthe ability to specifically bind to (i.e., hybridize specifically to)the same targets or samples as the probe from which they were derived(see discussion above). Such modifications are specifically covered byreference to the individual probes described herein.

“Antibody” refers to a polypeptide comprising a framework region from animmunoglobulin gene or fragments thereof that specifically binds andrecognizes an antigen. The recognized immunoglobulin genes include thekappa, lambda, alpha, gamma, delta, epsilon, and mu constant regiongenes, as well as the myriad immunoglobulin variable region genes. Lightchains are classified as either kappa or lambda. Heavy chains areclassified as gamma, mu, alpha, delta, or epsilon, which in turn definethe immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.Typically, the antigen-binding region of an antibody or its functionalequivalent will be most critical in specificity and affinity of binding.See Paul, Fundamental Immunology.

An exemplary immunoglobulin (antibody) structural unit comprises atetramer. Each tetramer is composed of two identical pairs ofpolypeptide chains, each pair having one “light” (about 25 kD) and one“heavy” chain (about 50-70 kD). The N-terminus of each chain defines avariable region of about 100 to 110 or more amino acids primarilyresponsible for antigen recognition. The terms variable light chain(V_(L)) and variable heavy chain (V_(H)) refer to these light and heavychains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number ofwell-characterized fragments produced by digestion with variouspeptidases. Thus, e.g., pepsin digests an antibody below the disulfidelinkages in the hinge region to produce F(ab)′₂, a dimer of Fab whichitself is a light chain joined to V_(H)-C_(H)1 by a disulfide bond. TheF(ab)′₂ may be reduced under mild conditions to break the disulfidelinkage in the hinge region, thereby converting the F(ab)′₂ dimer intoan Fab′ monomer. The Fab′ monomer is essentially Fab with part of thehinge region (see Fundamental Immunology (Paul ed., 3d ed. 1993). Whilevarious antibody fragments are defined in terms of the digestion of anintact antibody, one of skill will appreciate that such fragments may besynthesized de novo either chemically or by using recombinant DNAmethodology. Thus, the term antibody, as used herein, also includesantibody fragments either produced by the modification of wholeantibodies, or those synthesized de novo using recombinant DNAmethodologies (e.g., single chain Fv) or those identified using phagedisplay libraries (see, e.g., McCafferty et al., Nature 348:552-554(1990))

For preparation of antibodies, e.g., recombinant, monoclonal, orpolyclonal antibodies, many technique known in the art can be used (see,e.g., Kohler & Milstein, Nature 256:495-497 (1975); Kozbor et al.,Immunology Today 4:72 (1983); Cole et al., pp. 77-96 in MonoclonalAntibodies and Cancer Therapy (1985); Coligan, Current Protocols inImmunology (1991); Harlow & Lane, Antibodies, A Laboratory Manual(1988); and Goding, Monoclonal Antibodies: Principles and Practice (2ded. 1986)). Techniques for the production of single chain antibodies(U.S. Pat. No. 4,946,778) can be adapted to produce antibodies topolypeptides of this invention. Also, transgenic mice, or otherorganisms such as other mammals, may be used to express humanizedantibodies. Alternatively, phage display technology can be used toidentify antibodies and heteromeric Fab fragments that specifically bindto selected antigens (see, e.g., McCafferty et al., Nature 348:552-554(1990); Marks et al., Biotechnology 10:779-783 (1992)).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates real-time RT-PCR expression results for the CSMD1gene at 8p23. Matched benign and tumor pairs were used in this study andare indicated by black and white bars, respectively. Each tissue samplewas run in triplicate. The standard deviation for the cycle thresholdvalues of all three replicates was less than 0.3. Results are displayedrelative to a GUS reference gene. An asterisk denotes samples that arestage pT≧3.

FIG. 2 illustrates a box plot for BAC CTD-2220I9 in negative margincases. The boxplot compares the distribution of the log₂ratios ofCTD-2220I9 between progressors and non-progressors for those withnegative surgical margins. The solid horizontal lines are 1^(st), 2^(nd)(median) and 3^(rd) quartiles, respectively. The whiskers extend to 1.5SD away from the median where SD is a distribution of the value in asubgroup for this clone. The outlying points indicate outliers (furtherthan 1.5 SD away from the median).

FIG. 3 illustrates real-time RT-PCR expression results for the MEN1 geneat 11q13. Matched benign and tumor pairs were used in this study and areindicated by black and white bars, respectively. Each tissue sample wasrun in triplicate. The standard deviation for the cycle threshold valuesof all three replicates was less than 0.3. Results are displayedrelative to a GUS reference gene. An asterisk denotes samples thatshowed genomic gain at 11q13 by aCGH.

FIG. 4 illustrates a set of 39 candidate BAC biomarkers associated withmetastasis. Black bars represent tumors from patients (N_(max)=32) whodid not progress. Gray bars correspond to primary tumors from patients(N_(max)=12) who progressed to metastasis. Tumors represented by theblack and gray bars are from a single cohort, whereas white barsrepresent an independent cohort of metastatic tumors (N_(max)=15). Copynumber changes are reported only if they occur in each metastatic cohortat a frequency of ≧20% and in the non-progressor cohort<20% and werestatistically significant (p≦0.05). 1=EVI1 locus, 2=LIMK1 locus, 3=PDGFBlocus, 4=PTEN locus, 5=RB locus.

DETAILED DESCRIPTION OF THE INVENTION

I. Introduction

The present invention is based in part on the discovery that certainchromosomal copy number aberrations are associated with recurrence andmetastasis of prostate cancer. As demonstrated in the examples below, anincrease in the number of copies per cell of DNA in genomic locationsselected from the group consisting of 2qtel, 3q26.2, 3q26.32, 5p15.1,7p22.3, 7q11.23, 7q11.22, 7q22.1, 7q31.31, 8p23.2, 9q34.11, 11p15.5,11q13.1, 17q21.33, 17q25.3 and/or 22q13.1 and/or a decrease in thenumber of copies per cell of DNA in genomic locations selected from thegroup consisting of 4p13, 5q13.1, 5q14.3, 5q21.1, 5q21.2, 5q21.3,5q23.1, 6q14.1, 6q21, 8p22, 8p21.2, 8p12, 10q23.31, 13q14.11, 13q14.13,13q14.2, 13q14 and/or 16q23.1, compared to the number of copies per cellin non-cancer cells, indicates an increased risk of metastasis ofprostate cancer.

Moreover, the inventors have discovered that reduction of expression ofCSMD1 or loss of all or part of the CSMD1 gene is associated with anadvanced stage of prostate cancer. For example, pathological progressiveprostate cancer is associated with the loss of CSMD1. Accordingly,determining the level of expression or the copy number of CSMD1 in aprostate tumor cell is indicative of the stage of cancer.

In addition, the inventors have found that gain of genomic copies of theMEN1 gene or increased MEN1 expression is associated with tumors thatreoccurred following prostatectomy. Accordingly, determining the levelof expression or the copy number of MEN1 in a prostate tumor cell isuseful to predict cancers that are likely to reoccur following prostatesurgery.

II. Detecting Chromosomal Region or Parts Thereof.

Genomic instability is a hallmark of solid tumors, and virtually nosolid tumor exists that does not show some alterations of the genome.With the vast majority of tumors this instability is expressed at thelevel of the chromosomal complement, and thus is detectable bycytogenetic approaches (Mitelman, F., Catalog of Chromosome Aberrationsin Cancer, 5th Edition (New York: Wiley-Liss) (1994)). However,aneuploidy or chromosomal rearrangement per se is not indicative ofmalignancy and many benign tumors can have an aberrant karyotype(Mitelman, 1994). To efficiently take advantage of chromosomalabnormalities as a marker, it is useful to know characteristicaberrations of the tumors that are to be differentiated.

As discussed in the examples, detection of increases in the number ofcopies per cell in tumor samples of the following chromosomal locations:2qtel, 3q26.2, 3q26.32, 5p5.1, 7p22.3, 7q11.23, 7q11.22, 7q22.1,7q31.31, 9q34.11, 11p15.5, 17q21.33, 17q25.3 and/or 22q13.1, and/ordecreases in the number of copies per cell in tumor samples of thefollowing chromosomal locations: 4p13, 5q13.1, 5q14.3, 5q21.1, 5q21.2,5q21.3, 5q23.1, 6q14.1, 6q21, 8p22, 8p21.2, 8p12, 10q23.31, 13q14.11,13q14.13, 13q14.2, 13q14 and/or 16q23.1 is indicative of an increasedrisk of metastasis. These locations may be detected individually, or incombination. Thus, for example, in some embodiments, 1, 2, 3, 4, 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, or 31 of the above-listed chromosomal locations maybe detected to predict the risk of metastasis.

A number of the genomic locations of interest in the present inventionare bounded by probes as listed below: Boundary BAC Boundary BAC GenomicLocation clone clone 2qtel RP11-118M12 CTB-228K22 3q26.2 RP11-198G24RP11-141C22 3q26.32 RP11-148D23 CTB-364E3 3q26.3 CTB-364E3 RP11-118F45p15.1 RP11-269O14 RP11-5N11 7p22.3 RP1-164D18 RP11-96L18 7q11.22RP11-170H15 GS1-35C5 7q11.23 CTB-51J22 RP11-137E8 7q22.1 GS1-87A9RP4-747G18 7q31.31 CTB-185C18 GS1-74E4 9q34.1 RP11-62A6 CTD-2280C311p15.5 GS-137C7 RP11-120E20 17q21.33 RP11-110H20 RP5-32P19 17q25.3RP11-128J1 CTB-209F23 22q13.1 RP11-108C6 CTD-2194F18 4p13 RP11-113F10RP11-105F21 5q13.1 CTB-134O19 CTD-2113P14 5q14.3 RP11-275E14 RP11-45O115q21.1-5q21.2 RP11-204D12 RP11-277N18 5q21.3 RP11-252I13 RP11-13O215q23.1 RP11-81C5 RP11-15P5 6q14.1 RP11-28P18 RP11-32O2 6q21 RP11-73D20RP11-165E15 6q21 RP11-75C8 RP11-59F18 8p22 RP11-236O1 RP11-274K12 8p21.2RP11-158F9 RP11-70L1 8p21.2 RP11-164H24 RP11-199N14 8p21.2 RP11-199N14RP11-138J2 8p12 CTD-2020E14 RP11-122D17 10q23.31 CTB-46B12 RP11-67L1313q14.11 CTD-2037D17 RP11-53F19 13q14.11 RP11-53F19 RP11-9F13 13q14.11RP11-34K15 RP11-30N18 13q14.13 RP11-30N18 RP11-52B21 13q14.2 RP11-120G8RP1-58D13 13q14.3 RP1-58D13 RP11-211J11 16q23.1 RP11-217K3 RP11-284G28p23.1 CTB-12F4 RP11-548G17 11q13.1 RP11-82K8 RP11-140K14

In addition to the above table, copy number of MEN1 or CSMD1 genes, orgenes listed in Table 2 (e.g., coding sequences and/or upstream ordownstream elements such as promoters including, but not limited to,nucleotides 5 kb upstream of the initiation of translation ortranscription) may also be detected. Coding sequences of MEN1 and CSMD1are publicly available in Genbank accession numbers U93237 andNM_(—)033225, respectively. Probes for detection of MEN1 and CSMD1 areavailable commercially from, e.g., Applied Biosystems Inc., Foster City,Calif.).

Single or low-copy number probes that detect DNA within the genomiclocations are particularly useful for use in the invention. A list ofexemplary BAC clones that may be used to detect or generate probes todetect the various genomic locations is provided in Table 2 in theexamples. However, it should be understood that this list is notintended to limit the invention and other probes within the genomiclocations can also be used.

Several techniques that permit the study of chromosomal complement arewell known in the art. For example, fluorescence in-situ hybridization(FISH) can be used to study copy numbers of individual genetic loci orparticular regions on a chromosome (Pinkel et al., Proc. Natl. Acad.Sci. U.S.A. 85, 9138-42 (1988)). Comparative genomic hybridization (CGH)(Kallioniemi et al. Science 258, 818-21 (1992)) may also be used(Houldsworth et al. Am J Pathol 145, 1253-60 (1994)) to probe for copynumber changes of chromosomal regions as well as changes in chromosomenumber.

As appreciated by one of skill in the art, analysis of copy number canbe performed using multiple probes to a particular chromosome or can beperformed using a single probe, e.g., a centromeric probe, to detectchange in copy number. Probes useful in the methods described here areavailable from a number of sources. For instance, P1 clones areavailable from the DuPont P1 library (Shepard, et al., Proc. Natl. Acad.Sci. USA, 92: 2629 (1994), and available commercially from GenomeSystems. Various libraries spanning entire chromosomes are alsoavailable commercially (Clonetech, South San Francisco, Calif.), or fromthe Los Alamos National Laboratory.

In one set of embodiments, the hybridizations are performed on a solidsupport. For example, probes that selectively hybridize to specificchromosomal regions can be spotted onto a surface. Conveniently, thespots are placed in an ordered pattern, or array, and the placement ofthe probes on the array is recorded to facilitate later correlation ofresults. The nucleic acid samples are then hybridized to the array. Inone configuration, the multiplicity of nucleic acids (or other moieties)is attached to a single contiguous surface or to a multiplicity ofsurfaces juxtaposed to each other.

In an array format a large number of different hybridization reactionscan be run essentially “in parallel.” This provides rapid, essentiallysimultaneous, evaluation of a number of hybridizations in a single“experiment”. Methods of performing hybridization reactions in arraybased formats are well known to those of skill in the art (see, e.g.,Pastinen (1997) Genome Res. 7: 606-614; Jackson (1996) NatureBiotechnology 14:1685; Chee (1995) Science 274: 610; WO 96/17958).

Arrays, particularly nucleic acid arrays can be produced according to awide variety of methods well known to those of skill in the art (see,e.g., U.S. Pat. No. 6,040,138). For example, in a simple embodiment,“low density” arrays can simply be produced by spotting (e.g. by handusing a pipette) different nucleic acids at different locations on asolid support (e.g. a glass surface, a membrane, etc.).

This simple spotting approach has been automated to produce high densityspotted arrays (see, e.g., U.S. Pat. No. 5,807,522). This patentdescribes the use of an automated systems that taps a microcapillaryagainst a surface to deposit a small volume of a biological sample. Theprocess is repeated to generate high density arrays. Arrays can also beproduced using oligonucleotide synthesis technology. Thus, for example,U.S. Pat. No. 5,143,854 and PCT patent publication Nos. WO 90/15070 and92/10092 teach the use of light-directed combinatorial synthesis of highdensity oligonucleotide arrays.

In another embodiment the array, particularly a spotted array, caninclude genomic DNA, e.g. overlapping clones that provide a highresolution scan of the amplicon corresponding to the region of interest.Amplicon nucleic acid can be obtained from, e.g., MACs, YACs, BACs,PACs, PIs, cosmids, plasmids, inter-Alu PCR products of genomic clones,restriction digests of genomic clone, cDNA clones, amplification (e.g.,PCR) products, and the like.

In various embodiments, the array nucleic acids are derived frompreviously mapped libraries of clones spanning or including the targetsequences of the invention, as well as clones from other areas of thegenome, as described below. The arrays can be hybridized with a singlepopulation of sample nucleic acid or can be used with two differentiallylabeled collections (as with a test sample and a reference sample).

Many methods for immobilizing nucleic acids on a variety of solidsurfaces are known in the art. A wide variety of organic and inorganicpolymers, as well as other materials, both natural and synthetic, can beemployed as the material for the solid surface. Illustrative solidsurfaces include, e.g., nitrocellulose, nylon, glass, quartz, diazotizedmembranes (paper or nylon), silicones, polyformaldehyde, cellulose, andcellulose acetate. In addition, plastics such as polyethylene,polypropylene, polystyrene, and the like can be used. Other materialswhich may be employed include paper, ceramics, metals, metalloids,semiconductive materials, cermets or the like. In addition, substancesthat form gels can be used. Such materials include, e.g., proteins(e.g., gelatins), lipopolysaccharides, silicates, agarose andpolyacrylamides. Where the solid surface is porous, various pore sizesmay be employed depending upon the nature of the system.

Target elements of various sizes, ranging from 1 mm diameter down to 1μm can be used. Smaller target elements containing low amounts ofconcentrated, fixed probe DNA are used for high complexity comparativehybridizations since the total amount of sample available for binding toeach target element will be limited. Thus it is advantageous to havesmall array target elements that contain a small amount of concentratedprobe DNA so that the signal that is obtained is highly localized andbright. Such small array target elements are typically used in arrayswith densities greater than 10⁴/cm². Relatively simple approachescapable of quantitative fluorescent imaging of 1 cm² areas have beendescribed that permit acquisition of data from a large number of targetelements in a single image (see, e.g., Wittrup, Cytometry 16: 206-213,1994).

Arrays on solid surface substrates with much lower fluorescence thanmembranes, such as glass, quartz, or small beads, can achieve muchbetter sensitivity. Substrates such as glass or fused silica areadvantageous in that they provide a very low fluorescence substrate, anda highly efficient hybridization environment. Covalent attachment of thetarget nucleic acids to glass or synthetic fused silica can beaccomplished according to a number of known techniques. Nucleic acidscan be conveniently coupled to glass using commercially availablereagents. For instance, materials for preparation of silanized glasswith a number of functional groups are commercially available or can beprepared using standard techniques (see, e.g., Gait (1984)Oligonucleotide Synthesis: A Practical Approach, IRL Press, Wash.,D.C.). Quartz cover slips, which have at least 10-fold lowerautofluorescence than glass, can also be silanized.

Alternatively, the samples can be placed in separate wells or chambersand hybridized in their respective well or chambers. The art hasdeveloped robotic equipment permitting the automated delivery ofreagents to separate reaction chambers, including “chip” andmicrofluidic techniques, which allow the amount of the reagents used perreaction to be sharply reduced. Chip and microfluidic techniques aretaught in, for example, U.S. Pat. No. 5,800,690, Orchid, “Running onParallel Lines” New Scientist, Oct. 25, 1997, McCormick, et al., Anal.Chem. 69:2626-30 (1997), and Turgeon, “The Lab of the Future on CD-ROM?”Medical Laboratory Management Report. December 1997, p. 1. Automatedhybridizations on chips or in a microfluidic environment arecontemplated methods of practicing the invention.

Although microfluidic environments are one embodiment of the invention,they are not the only defined spaces suitable for performinghybridizations in a fluid environment. Other such spaces includestandard laboratory equipment, such as the wells of microtiter plates,Petri dishes, centrifuge tubes, or the like can be used.

In situ hybridization assays are well known (e.g., Angerer (1987) Meth.Enzymol 152: 649). Generally, in situ hybridization comprises thefollowing major steps: (1) fixation of tissue or biological structure tobe analyzed; (2) prehybridization treatment of the biological structureto increase accessibility of target DNA, and to reduce nonspecificbinding; (3) hybridization of the mixture of nucleic acids to thenucleic acid in the biological structure or tissue; (4)post-hybridization washes to remove nucleic acid fragments not bound inthe hybridization and (5) detection of the hybridized nucleic acidfragments. The reagent used in each of these steps and the conditionsfor use vary depending on the particular application.

In a typical in situ hybridization assay, cells are fixed to a solidsupport, typically a glass slide. If a nucleic acid is to be probed, thecells are typically denatured with heat or alkali. The cells are thencontacted with a hybridization solution at a moderate temperature topermit annealing of labeled probes specific to the nucleic acid sequenceencoding the protein. The targets (e.g., cells) are then typicallywashed at a predetermined stringency or at an increasing stringencyuntil an appropriate signal to noise ratio is obtained.

The probes are typically labeled, e.g., with radioisotopes orfluorescent reporters. The preferred size range is from about 200 bp toabout 1000 bases, more preferably between about 400 to about 800 bp fordouble stranded, nick translated nucleic acids.

In some applications it is necessary to block the hybridization capacityof repetitive sequences. Thus, in some embodiments, human genomic DNA orCot-1 DNA is used to block non-specific hybridization.

In Comparative Genomic Hybridization (CGH) methods a first collection of(sample) nucleic acids (e.g. from a possible tumor) is labeled with afirst label, while a second collection of (control) nucleic acids (e.g.from a healthy cell/tissue) is labeled with a second label. The ratio ofhybridization of the nucleic acids is determined by the ratio of the two(first and second) labels binding to each fiber in the array. Wherethere are chromosomal deletions or multiplications, differences in theratio of the signals from the two labels will be detected and the ratiowill provide a measure of the copy number.

Hybridization protocols suitable for use with the methods of theinvention are described, e.g., in Albertson (1984) EMBO J. 3: 1227-1234;Pinkel (1988) Proc. Natl. Acad. Sci. USA 85: 9138-9142; EPO Pub. No.430,402; Methods in Molecular Biology, Vol. 33: In Situ HybridizationProtocols, Choo, ed., Humana Press, Totowa, N.J. (1994), etc. In someembodiments, the hybridization protocol of Pinkel et al. (1998) NatureGenetics 20:207-211 or of Kallioniemi (1992) Proc. Natl. Acad Sci USA89:5321-5325 (1992) is often used.

In general, there is a tradeoff between hybridization specificity(stringency) and signal intensity. Thus, in some embodiments, the washis performed at the highest stringency that produces consistent resultsand that provides a signal intensity greater than approximately 10% ofthe background intensity. Thus, in some embodiments, the hybridizedarray may be washed at successively higher stringency solutions and readbetween each wash. Analysis of the data sets thus produced will reveal awash stringency above which the hybridization pattern is not appreciablyaltered and which provides adequate signal for the particular probes ofinterest.

In some embodiments, background signal is reduced by the use of adetergent (e.g., C-TAB) or a blocking reagent (e.g., sperm DNA, cot-1DNA, etc.) during the hybridization to reduce non-specific binding. Thehybridization may be performed, for example, in the presence of about0.1 to about 0.5 mg/ml DNA (e.g., cot-1 DNA). The use of blocking agentsin hybridization is well known to those of skill in the art (see, e.g.,Chapter 8 in P. Tijssen, supra.)

Methods of optimizing hybridization conditions are well known to thoseof skill in the art (see, e.g., Tijssen (1993) Laboratory Techniques inBiochemistry and Molecular Biology, Vol. 24: Hybridization With NucleicAcid Probes, Elsevier, N.Y.).

Optimal conditions are also a function of the sensitivity of label(e.g., fluorescence) detection for different combinations of substratetype, fluorochrome, excitation and emission bands, spot size and thelike. Low fluorescence background membranes can be used (see, e.g., Chu(1992) Electrophoresis 13:105-114). The sensitivity for detection ofspots (“target elements”) of various diameters on the candidatemembranes can be readily determined by, e.g., spotting a dilution seriesof fluorescently end labeled DNA fragments. These spots are then imagedusing conventional fluorescence microscopy. The sensitivity, linearity,and dynamic range achievable from the various combinations offluorochrome and solid surfaces (e.g., membranes, glass, fused silica)can thus be determined. Serial dilutions of pairs of fluorochrome inknown relative proportions can also be analyzed. This determines theaccuracy with which fluorescence ratio measurements reflect actualfluorochrome ratios over the dynamic range permitted by the detectorsand fluorescence of the substrate upon which the probe has been fixed.

Other nucleic acid hybridization formats are also known to those skilledin the art. Such formats are described, for example in Sambrook andRussell, supra. These includes analyses such as Southern blotting. Thesensitivity of the hybridization assays may also be enhanced through useof a nucleic acid amplification system that multiplies the targetnucleic acid being detected. Examples of such systems include thepolymerase chain reaction (PCR) system and the ligase chain reaction(LCR) system. Other methods recently described in the art are thenucleic acid sequence based amplification (NASBAO, Cangene, Mississauga,Ontario) and Q Beta Replicase systems.

Ploidy, i.e., chromosome number, may also be determined usingquantitative PCR such as real-time PCR (see, e.g., Suzuki et al., CancerRes. 60:5405-9 (2000)). For example, quantitative microsatelliteanalysis (QUMA) can be performed for rapid measurement of relative DNAsequence copy number. In QUMA, the copy number of a test locus relativeto a pooled reference is assessed using quantitative, real-time PCRamplification of loci carrying simple sequence repeats. Use of simplesequence repeats is advantageous because of the large numbers that aremapped precisely.

Additional protocols for quantitative PCR are provided in Innis et al.(1990) PCR Protocols, A Guide to Methods and Applications, AcademicPress, Inc. N.Y.).

Labeling and Detection of Nucleic Acids

The hybridized nucleic acids are typically detected by detecting one ormore labels attached to the sample or probe nucleic acids. The labelsmay be incorporated by any of a number of means well known to those ofskill in the art. Means of attaching labels to nucleic acids include,for example nick translation or end-labeling (e.g. with a labeled RNA)by phosphorylating (e.g., with a kinase) of the nucleic acid andsubsequent attachment (ligation) of a nucleic acid linker joining thesample nucleic acid to a label (e.g., a fluorophore). A wide variety oflinkers for the attachment of labels to nucleic acids are also known. Inaddition, intercalating dyes and fluorescent nucleotides can also beused.

Detectable labels suitable for use in the present invention include anycomposition detectable by spectroscopic, photochemical, biochemical,immunochemical, electrical, optical or chemical means. Useful labels inthe present invention include biotin for staining with labeledstreptavidin conjugate, magnetic beads (e.g., Dynabeads™), fluorescentdyes (e.g., fluorescein, Texas red, rhodamine, green fluorescentprotein, and the like, see, e.g., Molecular Probes, Eugene, Oreg., USA),radiolabels (e.g., ³H, ¹²⁵I, ³⁵S, ¹⁴C, or ³²P), enzymes (e.g., horseradish peroxidase, alkaline phosphatase and others commonly used in anELISA), and colorimetric labels such as colloidal gold (e.g., goldparticles in the 40-80 nm diameter size range scatter green light withhigh efficiency) or colored glass or plastic (e.g., polystyrene,polypropylene, latex, etc.) beads. Patents teaching the use of suchlabels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350;3,996,345; 4,277,437; 4,275,149; and 4,366,241.

A fluorescent label is useful because it provides a very strong signalwith low background. It is also optically detectable at high resolutionand sensitivity through a quick scanning procedure. The nucleic acidsamples can all be labeled with a single label, e.g., a singlefluorescent label. Alternatively, in another embodiment, differentnucleic acid samples can be simultaneously hybridized where each nucleicacid sample has a different label. For instance, one target could have agreen fluorescent label and a second target could have a red fluorescentlabel. The scanning step will distinguish cites of binding of the redlabel from those binding the green fluorescent label. Each nucleic acidsample (target nucleic acid) can be analyzed independently from oneanother.

Suitable chromogens which can be employed include those molecules andcompounds which absorb light in a distinctive range of wavelengths sothat a color can be observed or, alternatively, which emit light whenirradiated with radiation of a particular wave length or wave lengthrange, e.g., fluorescers.

Desirably, fluorescers should absorb light above about 300 nm,preferably about 350 nm, and more preferably above about 400 nm, usuallyemitting at wavelengths greater than about 10 nm higher than thewavelength of the light absorbed. It should be noted that the absorptionand emission characteristics of the bound dye can differ from theunbound dye. Therefore, when referring to the various wavelength rangesand characteristics of the dyes, it is intended to indicate the dyes asemployed and not the dye which is unconjugated and characterized in anarbitrary solvent.

Fluorescers are particularly useful because by irradiating a fluorescerwith light, one can obtain a plurality of emissions. Thus, a singlelabel can provide for a plurality of measurable events.

Detectable signal can also be provided by chemiluminescent andbioluminescent sources. Chemiluminescent sources include a compoundwhich becomes electronically excited by a chemical reaction and can thenemit light which serves as the detectable signal or donates energy to afluorescent acceptor. Alternatively, luciferins can be used inconjunction with luciferase or lucigenins to provide bioluminescence.Spin labels are provided by reporter molecules with an unpaired electronspin which can be detected by electron spin resonance (ESR)spectroscopy. Exemplary spin labels include organic free radicals,transitional metal complexes, particularly vanadium, copper, iron, andmanganese, and the like. Exemplary spin labels include nitroxide freeradicals.

The label may be added to the target (sample) nucleic acid(s) prior to,or after the hybridization. So called “direct labels” are detectablelabels that are directly attached to or incorporated into the target(sample) nucleic acid prior to hybridization. In contrast, so called“indirect labels” are joined to the hybrid duplex after hybridization.Often, the indirect label is attached to a binding moiety that has beenattached to the target nucleic acid prior to the hybridization. Thus,for example, the target nucleic acid may be biotinylated before thehybridization. After hybridization, an avidin-conjugated fluorophorewill bind the biotin bearing hybrid duplexes providing a label that iseasily detected. The nucleic acid probe may also be labeled withdigoxigenin and then detected with an antibody that is labeled with afluorochrom, or an enzyme such as horseradish peroxidase or alkalinephosphatase. For a detailed review of methods of labeling nucleic acidsand detecting labeled hybridized nucleic acids see Laboratory Techniquesin Biochemistry and Molecular Biology, Vol. 24: Hybridization WithNucleic Acid Probes, P. Tijssen, ed. Elsevier, N.Y., (1993)).

Fluorescent labels are easily added during an in vitro transcriptionreaction. Thus, for example, fluorescein labeled UTP and CTP can beincorporated into the RNA produced in an in vitro transcription.

The labels can be attached directly or through a linker moiety. Ingeneral, the site of label or linker-label attachment is not limited toany specific position. For example, a label may be attached to anucleoside, nucleotide, or analogue thereof at any position that doesnot interfere with detection or hybridization as desired. For example,certain Label-ON Reagents from Clontech (Palo Alto, Calif.) provide forlabeling interspersed throughout the phosphate backbone of anoligonucleotide and for terminal labeling at the 3′ and 5′ ends. Asshown for example herein, labels can be attached at positions on theribose ring or the ribose can be modified and even eliminated asdesired. The base moieties of useful labeling reagents can include thosethat are naturally occurring or modified in a manner that does notinterfere with the purpose to which they are put. Modified bases includebut are not limited to 7-deaza A and G, 7-deaza-8-aza A and G, and otherheterocyclic moieties.

It will be recognized that fluorescent labels are not to be limited tosingle species organic molecules, but include inorganic molecules,multi-molecular mixtures of organic and/or inorganic molecules,crystals, heteropolymers, and the like. Thus, for example, CdSe—CdScore-shell nanocrystals enclosed in a silica shell can be easilyderivatized for coupling to a biological molecule (Bruchez et al. (1998)Science, 281: 2013-2016). Similarly, highly fluorescent quantum dots(zinc sulfide-capped cadmium selenide) have been covalently coupled tobiomolecules for use in ultrasensitive biological detection (Warren andNie (1998) Science, 281: 2016-2018).

IV. Detecting Gene Expression

As described above, it has been discovered that increased expression ofMEN1 compared to a healthy control indicates a risk ofpost-prostatectomy re-occurrence of cancer. Moreover, a decrease inCSMD1 expression compared to a healthy control indicates an advancedstage of prostate cancer, i.e., a cancer that is likely an aggressivecancer that will reoccur and/or metastasize. In addition, as displayedin Table 2 in the examples, genomic regions whose increased or decreasedcopy number are associated with metastasis comprise a number of genes,whose increased or decreased expression, respectively, is associatedwith metastasis. Accordingly, the present invention provides for methodsof detecting expression of MEN1 and/or CSMD1 expression and/orexpression of any or all of the genes listed in Table 2, includingexpression of mRNAs or proteins encoded by the genes.

Typically, the level of a polynucleotide or polypeptide of interest willbe detected in a biological sample. A “biological sample” refers to acell or population of cells or a quantity of tissue or fluid from ananimal. Most often, the sample has been removed from an animal, but theterm “biological sample” can also refer to cells or tissue analyzed invivo, i.e., without removal from the animal. Typically, a “biologicalsample” will contain cells from the animal, but the term can also referto noncellular biological material, such as noncellular fractions ofblood, saliva, or urine, that can be used to measure thecancer-associated polynucleotide or polypeptide levels. Numerous typesof biological samples can be used in the present invention, including,but not limited to, a tissue biopsy, a blood sample, a buccal scrape, asaliva sample, or a nipple discharge.

As used herein, a “tissue biopsy” refers to an amount of tissue removedfrom an animal for diagnostic analysis. In a patient with cancer, tissuemay be removed from a tumor, allowing the analysis of cells within thetumor. “Tissue biopsy” can refer to any type of biopsy, such as needlebiopsy, fine needle biopsy, surgical biopsy, etc.

In one embodiment, the presence of cancer is evaluated by determiningthe level of expression of mRNA encoding a protein of interest. Methodsof evaluating RNA expression of a particular gene are well known tothose of skill in the art, and include, inter alia, hybridization andamplification based assays.

Direct Hybridization-Based Assays

Methods of detecting and/or quantifying the level of gene transcripts ofinterest (mRNA or cDNA made therefrom) using nucleic acid hybridizationtechniques are known to those of skill in the art. For example, onemethod for evaluating the presence, absence, or quantity ofpolynucleotides involves a northern blot. Gene expression levels canalso be analyzed by techniques known in the art, e.g., dot blotting, insitu hybridization, RNase protection, probing DNA microchip arrays, andthe like.

Amplification-Based Assays

In another embodiment, amplification-based assays are used to measurethe expression level of a gene of interest. In such an assay, thenucleic acid sequences act as a template in an amplification reaction(e.g., Polymerase Chain Reaction, or PCR). In a quantitativeamplification, the amount of amplification product will be proportionalto the amount of template in the original sample. Comparison toappropriate controls provides a measure of the level of expression ofthe gene of interest in the sample. Methods of quantitativeamplification are well known to those of skill in the art. Detailedprotocols for quantitative PCR are provided, e.g., in Innis et al.(1990) PCR Protocols, A Guide to Methods and Applications, AcademicPress, Inc. N.Y.). The known nucleic acid sequences for the genes listedherein is sufficient to enable one of skill to routinely select primersto amplify any portion of the gene. Exemplary sequences for the MEN1 andCSMD1 cDNAs can be found in Genbank accession numbers U93236 andNM_(—)033225, respectively. Probes to identify the genomic regionsidentified in this application include, but are not limited to, the BACslisted in Table 2.

In one embodiment, a TaqMan™ based assay is used to quantify thecancer-associated polynucleotides. TaqMan based assays use a fluorogenicoligonucleotide probe that contains a 5′ fluorescent dye and a 3′quenching agent. The probe hybridizes to a PCR product, but cannotitself be extended due to a blocking agent at the 3′ end. When the PCRproduct is amplified in subsequent cycles, the 5′ nuclease activity ofthe polymerase, e.g., AmpliTaq, results in the cleavage of the TaqManprobe. This cleavage separates the 5′ fluorescent dye and the 3′quenching agent, thereby resulting in an increase in fluorescence as afunction of amplification (see, for example, literature provided byPerkin-Elmer, e.g., www2.perkin-elmer.com).

Other suitable amplification methods include, but are not limited to,ligase chain reaction (LCR) (see, Wu and Wallace (1989) Genomics 4: 560,Landegren et al. (1988) Science 241: 1077, and Barringer et al. (1990)Gene 89: 117), transcription amplification (Kwoh et al. (1989) Proc.Natl. Acad. Sci. USA 86: 1173), self-sustained sequence replication(Guatelli et al. (1990) Proc. Nat. Acad. Sci. USA 87: 1874), dot PCR,and linker adapter PCR, etc.

Production of Antibodies and Immunological Detection

Polypeptides encoded by the genes described herein can be detectedand/or quantified by any methods known to those of skill in the art.Samples can be from any biological source, including e.g., tissuebiopsies, tumors, and bodily fluids such as blood, urine, semen, etc.

In some embodiments, antibodies can also be used to detect polypeptidesencoded by the genes described herein. Antibodies to these polypeptidescan be produced using well known techniques (see, e.g., Harlow & Lane,Antibodies: A Laboratory Manual (1988) and Harlow & Lane, UsingAntibodies (1999); Coligan, Current Protocols in Immunology (1991);Goding, Monoclonal Antibodies: Principles and Practice (2d ed. 1986);and Kohler & Milstein, Nature 256:495-497 (1975)). Such techniquesinclude antibody preparation by selection of antibodies from librariesof recombinant antibodies in phage or similar vectors, as well aspreparation of polyclonal and monoclonal antibodies by immunizingrabbits or mice (see, e.g., Huse et al., Science 246:1275-1281 (1989);Ward et al., Nature 341:544-546 (1989)). Such antibodies are typicallyused for diagnostic or prognostic applications, e.g., in the detectionof lung or breast cancer.

Polypeptides of the invention or a fragment thereof may be used toproduce antibodies specifically reactive with the polypeptide. Forexample, a recombinant polypeptide or an antigenic fragment thereof, maybe isolated. Recombinant protein is a useful immunogen for theproduction of monoclonal or polyclonal antibodies. Alternatively, asynthetic peptide derived from the sequences disclosed herein andconjugated to a carrier protein can be used as an immunogen. Naturallyoccurring protein may also be used either in pure or impure form. Theproduct is then injected into an animal capable of producing antibodies.Either monoclonal or polyclonal antibodies may be generated, forsubsequent use in immunoassays to measure the protein.

Typically, polyclonal antisera with a titer of 10⁴ or greater may beselected and tested for their cross reactivity against proteins otherthan the polypeptides of interest using a competitive bindingimmunoassay. Specific polyclonal antisera and monoclonal antibodies willusually bind with a K_(d) of at least about 0.1 mM, more usually atleast about 1 μM, optionally at least about 0.1 μM or better, andoptionally 0.01 μM or better. For cross-reactivity determination,typically immunoabsorbed antisera may be used in a competitive bindingimmunoassay to compare a second protein to the polypeptide of interest.In order to make this comparison, the two proteins are each assayed at awide range of concentrations and the amount of each protein required toinhibit 50% of the binding of the antisera to the immobilized protein isdetermined. If the amount of the second protein required to inhibit 50%of binding is less than 10 times the amount of the antigenic protein ofinterest that is required to inhibit 50% of binding, then the secondprotein is said to specifically bind to the polyclonal antibodiesgenerated to the SOCS-3 immunogen.

Once specific antibodies are available, binding interactions with theproteins of interest can be detected by a variety of immunoassaymethods. For a review of immunological and immuno assay procedures, seeBasic and Clinical Immunology (Stites & Terr eds., 7th ed. 1991).Moreover, the immunoassays of the present invention can be performed inany of several configurations, which are reviewed extensively in EnzymeImmunoassay (Maggio, ed., 1980); and Harlow & Lane, supra).

Immunoassays also often use a labeling agent to specifically bind to andlabel the complex formed by the antibody and antigen. The labeling agentmay itself be one of the moieties comprising the antibody/antigencomplex. Thus, the labeling agent may be a labeled polypeptide or alabeled antibody that binds the protein of interest. Alternatively, thelabeling agent may be a third moiety, such as a secondary antibody, thatspecifically binds to the antibody/antigen complex (a secondary antibodyis typically specific to antibodies of the species from which the firstantibody is derived). Other proteins capable of specifically bindingimmunoglobulin constant regions, such as protein A or protein G may alsobe used as the labeling agent. These proteins exhibit a strongnon-immunogenic reactivity with immunoglobulin constant regions from avariety of species (see, e.g., Kronval et al., J. Immunol. 111:1401-1406(1973); Akerstrom et al., J. Immunol. 135:2589-2542 (1985)). Thelabeling agent can be modified with a detectable moiety, such as biotin,to which another molecule can specifically bind, such as streptavidin. Avariety of detectable moieties are well known to those skilled in theart.

Commonly used assays include noncompetitive assays, e.g., sandwichassays, and competitive assays. In competitive assays, the amount ofpolypeptide present in the sample is measured indirectly by measuringthe amount of a known, added (exogenous) polypeptide of interestdisplaced (competed away) from an antibody that binds by the unknownpolypeptide present in a sample. Commonly used assay formats includeimmunoblots, which are used to detect and quantify the presence ofprotein in a sample. Other assay formats include liposome immunoassays(LIA), which use liposomes designed to bind specific molecules (e.g.,antibodies) and release encapsulated reagents or markers. The releasedchemicals are then detected according to standard techniques (see Monroeet al., Amer. Clin. Prod. Rev. 5:34-41(1986)).

The particular label or detectable group used in the assay is not acritical aspect of the invention, as long as it does not significantlyinterfere with the specific binding of the antibody used in the assay.The detectable group can be any material having a detectable physical orchemical property. Such detectable labels have been well-developed inthe field of immunoassays and, in general, most any label useful in suchmethods can be applied to the present invention. Thus, a label is anycomposition detectable by spectroscopic, photochemical, biochemical,immunochemical, electrical, optical or chemical means. Useful labels inthe present invention include magnetic beads (e.g., DYNABEADS™),fluorescent dyes (e.g., fluorescein isothiocyanate, Texas red,rhodamine, and the like), radiolabels, enzymes (e.g., horse radishperoxidase, alkaline phosphatase and others commonly used in an ELISA),and colorimetric labels such as colloidal gold or colored glass orplastic beads (e.g., polystyrene, polypropylene, latex, etc.).

The label may be coupled directly or indirectly to the desired componentof the assay according to methods well known in the art. As indicatedabove, a wide variety of labels may be used, with the choice of labeldepending on sensitivity required, ease of conjugation with thecompound, stability requirements, available instrumentation, anddisposal provisions.

Non-radioactive labels are often attached by indirect means. Generally,a ligand molecule (e.g., biotin) is covalently bound to the molecule.The ligand then binds to another molecule (e.g., streptavidin), which iseither inherently detectable or covalently bound to a signal system,such as a detectable enzyme, a fluorescent compound, or achemiluminescent compound. The ligands and their targets can be used inany suitable combination with antibodies that recognize the polypeptideof interest, or secondary antibodies that recognize an antibody thatbinds the polypeptide.

The molecules can also be conjugated directly to signal generatingcompounds, e.g., by conjugation with an enzyme or fluorophore. Enzymesof interest as labels will primarily be hydrolases, particularlyphosphatases, esterases and glycosidases, or oxidotases, particularlyperoxidases. Fluorescent compounds include fluorescein and itsderivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc.Chemiluminescent compounds include luciferin, and2,3-dihydrophthalazinediones, e.g., luminol. For a review of variouslabeling or signal producing systems that may be used, see U.S. Pat. No.4,391,904.

Means of detecting labels are well known to those of skill in the art.Thus, for example, where the label is a radioactive label, means fordetection include a scintillation counter or photographic film as inautoradiography. Where the label is a fluorescent label, it may bedetected by exciting the fluorochrome with the appropriate wavelength oflight and detecting the resulting fluorescence. The fluorescence may bedetected visually, by means of photographic film, by the use ofelectronic detectors such as charge coupled devices (CCDs) orphotomultipliers and the like. Similarly, enzymatic labels may bedetected by providing the appropriate substrates for the enzyme anddetecting the resulting reaction product. Finally simple colorimetriclabels may be detected simply by observing the color associated with thelabel. Thus, in various dipstick assays, conjugated gold often appearspink, while various conjugated beads appear the color of the bead.

Some assay formats do not require the use of labeled components. Forinstance, agglutination assays can be used to detect the presence of thetarget antibodies. In this case, antigen-coated particles areagglutinated by samples comprising the target antibodies. In thisformat, none of the components need be labeled and the presence of thetarget antibody is detected by simple visual inspection.

V. Identification of Modulators of Genes and Polypeptides of theInvention

Modulators, i.e., inhibitors of those gene products listed as gainingcopy number in prostate cancer in Table 2 or MEN1, or activators ofthose gene products listed as losing copy numbers in prostate cancer inTable 2 or CSMD1, are useful for treating cancer, including prostatecancer. For example, administration of the inhibitors or activators canbe used to treat prostate cancer or at least reduce the progression orsymptoms of prostate cancer and/or metastasis of the cancer and can beused in combination with prostate surgery or in the absence of surgery.

A. Agents that Modulate Polypeptides Described Herein

The agents tested as modulators of polypeptides of the invention can beany small chemical compound, or a biological entity, such as a protein,sugar, nucleic acid or lipid. Typically, test compounds will be smallchemical molecules and peptides. Essentially any chemical compound canbe used as a potential modulator or ligand in the assays of theinvention, although most often compounds that can be dissolved inaqueous or organic (especially DMSO-based) solutions are used. Theassays are designed to screen large chemical libraries by automating theassay steps and providing compounds from any convenient source toassays, which are typically run in parallel (e.g., in microtiter formatson microtiter plates in robotic assays). Modulators also include agentsdesigned to modulate (increase or decrease) the level of mRNA encodingpolypeptide (e.g., antisense molecules, ribozymes, DNAzymes, smallinhibitory RNAs and the like) or the level of translation from an mRNA(e.g., translation blockers such as an antisense molecules that arecomplementary to translation start or other sequences on an mRNAmolecule). It will be appreciated that there are many suppliers ofchemical compounds, including Sigma (St. Louis, Mo.), Aldrich (St.Louis, Mo.), Sigma-Aldrich (St. Louis, Mo.), FlukaChemika-Biochemica-Analytika (Buchs, Switzerland) and the like.

In some embodiments, high throughput screening methods involve providinga combinatorial chemical or peptide library containing a large number ofpotential therapeutic compounds (potential modulator compounds). Such“combinatorial chemical libraries” or “ligand libraries” are thenscreened in one or more assays, as described herein, to identify thoselibrary members (particular chemical species or subclasses) that displaya desired characteristic activity. The compounds thus identified canserve as conventional “lead compounds” or can themselves be used aspotential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemicalcompounds generated by either chemical synthesis or biologicalsynthesis, by combining a number of chemical “building blocks” such asreagents. For example, a linear combinatorial chemical library such as apolypeptide library is formed by combining a set of chemical buildingblocks (amino acids) in every possible way for a given compound length(i.e., the number of amino acids in a polypeptide compound). Millions ofchemical compounds can be synthesized through such combinatorial mixingof chemical building blocks.

Preparation and screening of combinatorial chemical libraries is wellknown to those of skill in the art. Such combinatorial chemicallibraries include, but are not limited to, peptide libraries (see, e.g.,U.S. Pat. No. 5,010,175, Furka, Int. J. Pept. Prot. Res. 37:487-493(1991) and Houghton et al., Nature 354:84-88 (1991)). Other chemistriesfor generating chemical diversity libraries can also be used. Suchchemistries include, but are not limited to: peptoids (e.g., PCTPublication No. WO 91/19735), encoded peptides (e.g., PCT Publication WO93/20242), random bio-oligomers (e.g., PCT Publication No. WO 92/00091),benzodiazepines (e.g., U.S. Pat. No. 5,288,514), diversomers such ashydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Nat.Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagiharaet al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidalpeptidomimetics with glucose scaffolding (Hirschmann et al., J. Amer.Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of smallcompound libraries (Chen et al., J. Amer. Chem. Soc. 116:2661 (1994)),oligocarbamates (Cho et al., Science 261:1303 (1993)), and/or peptidylphosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)), nucleicacid libraries (see Ausubel, Berger and Sambrook, all supra), peptidenucleic acid libraries (see, e.g., U.S. Pat. No. 5,539,083), antibodylibraries (see, e.g., Vaughn et al., Nature Biotechnology, 14(3):309-314(1996) and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang etal., Science, 274:1520-1522 (1996) and U.S. Pat. No. 5,593,853), smallorganic molecule libraries (see, e.g., benzodiazepines, Baum C&EN, Jan.18, page 33 (1993); isoprenoids, U.S. Pat. No. 5,569,588;thiazolidinones and metathiazanones, U.S. Pat. No. 5,549,974;pyrrolidines, U.S. Pat. Nos. 5,525,735 and 5,519,134; morpholinocompounds, U.S. Pat. No. 5,506,337; benzodiazepines, U.S. Pat. No.5,288,514, and the like).

Devices for the preparation of combinatorial libraries are commerciallyavailable (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, LouisvilleKy., Symphony, Rainin, Woburn, Mass., 433A Applied Biosystems, FosterCity, Calif., 9050 Plus, Millipore, Bedford, Mass.). In addition,numerous combinatorial libraries are themselves commercially available(see, e.g., ComGenex, Princeton, N.J., Tripos, Inc., St. Louis, Mo., 3DPharmaceuticals, Exton, Pa., Martek Biosciences, Columbia, Md., etc.).

B. Methods of Screening for Modulators of the Polypeptides of theInvention

A number of different screening protocols can be utilized to identifyagents that modulate the level of expression or activity of apolynucleotide of a polypeptide of the invention in cells, particularlymammalian cells, and especially human cells. In general terms, thescreening methods involve screening a plurality of agents to identify anagent that modulates the activity of a polypeptide of the invention by,e.g., binding to the polypeptide, preventing an inhibitor or activatorfrom binding to the polypeptide, increasing association of an inhibitoror activator with the polypeptide, or activating or inhibitingexpression of the polypeptide.

Any cell expressing a full-length polypeptide of the invention or afragment thereof can be used to identify modulators. In someembodiments, the cells are eukaryotic cells lines transformed to expressa heterologous polypeptide as listed herein.

1. Polypeptide Binding Assays

Preliminary screens can be conducted by screening for agents capable ofbinding to polypeptides described herein, as at least some of the agentsso identified are likely modulators of a polypeptide of the invention.Binding assays are also useful, e.g., for identifying endogenousproteins that interact with the polypeptides described herein. Forexample, antibodies or other molecules that bind polypeptides of theinvention can be identified in binding assays. Binding assays caninvolve, but are not limited to, use of isolated polypeptides, crudeextracts, or cell-based assays.

Binding assays can involve contacting a polypeptide with one or moretest agents and allowing sufficient time for the protein and test agentsto form a binding complex. Any binding complexes formed can be detectedusing any of a number of established analytical techniques. Proteinbinding assays include, but are not limited to, methods that measureco-precipitation or co-migration on non-denaturing SDS-polyacrylamidegels, and co-migration on Western blots (see, e.g., Bennet, J. P. andYamamura, H. I. (1985) “Neurotransmitter, Hormone or Drug ReceptorBinding Methods,” in Neurotransmitter Receptor Binding (Yamamura, H. I.,et al., eds.), pp. 61-89. Other binding assays involve the use of massspectrometry or NMR techniques to identify molecules bound thepolypeptide or displacement of labeled substrates. The polypeptides usedin these assays can be naturally expressed, cloned or synthesized.

In addition, mammalian or yeast two-hybrid approaches (see, e.g.,Bartel, P. L. et. al. Methods Enzymol, 254:241 (1995)) can be used toidentify polypeptides or other molecules that interact or bind to thepolypeptide when expressed together in a host cell.

2. Polypeptide Activity

Polypeptide activity can be assessed using a variety of in vitro and invivo assays to determine functional, chemical, and physical effects toidentify modulators. T

Samples or assays that are treated with a potential inhibitor oractivator (e.g., a “test compound”) are compared to control sampleswithout the test compound, to examine the extent of modulation. Controlsamples (untreated with candidate compounds are assigned a relativeactivity value of 100. Inhibition of the polypeptides of the inventionis achieved when the activity value relative to the control is about90%, optionally 50%, optionally 25-0%. Activation of the polypeptides ofthe invention is achieved when the activity value relative to thecontrol is at least about 110%, optionally 150%, 500%, or more.

3. Expression Assays

Screening assays for a compound that modulates the expression ofpolynucleotides and polypeptides described herein are also provided.Screening methods generally involve conducting cell-based assays inwhich test compounds are contacted with one or more cells expressing oneor more polypeptide of the invention, and then detecting an increase ordecrease in expression (either transcript or translation product).Assays can be performed with any cells that express a polypeptide.

Expression can be detected in a number of different ways. As describedherein, the expression level of a polynucleotide can be determined byprobing the mRNA expressed in a cell with a probe that specificallyhybridizes with an encoded transcript (or complementary nucleic acidderived therefrom). Alternatively, a polypeptide can be detected usingimmunological methods, e.g., an assay in which a cell lysate is probedwith antibodies that specifically bind to the polypeptide.

Reporter systems can also be used to identify modulators of expression.A variety of different types of cells can be utilized in promoterreporter assays. Cells that do not endogenously express a particularpolypeptide of interest can be prokaryotic, but are preferablyeukaryotic. The eukaryotic cells can be any of the cells typicallyutilized in generating cells that harbor recombinant nucleic acidconstructs. Exemplary eukaryotic cells include, but are not limited to,yeast, and various higher eukaryotic cells such as the HEK293, HepG2,COS, CHO and HeLa cell lines.

Various controls can be conducted to ensure that an observed activity isauthentic including running parallel reactions with cells that lack thereporter construct or by not contacting a cell harboring the reporterconstruct with test compound. Compounds can also be further validated asdescribed below.

4. Validation

Agents that are initially identified by any of the foregoing screeningmethods can be further tested to validate the activity. Validity of themodulators, for example, can be tested in suitable animal models. Thebasic format of such methods involves administering a lead compoundidentified during an initial screen to an animal that serves as a modelfor human disease (e.g., prostate cancer) and/or determining ifexpression or activity of a polypeptide or polynucleotide of interest isin fact modulated.

C. Solid Phase and Soluble High Throughput Assays

In the high throughput assays of the invention, it is possible to screenup to several thousand different modulators or ligands in a single day.In particular, each well of a microtiter plate can be used to run aseparate assay against a selected potential modulator, or, ifconcentration or incubation time effects are to be observed, every 5-10wells can test a single modulator. Thus, a single standard microtiterplate can assay about 100 (e.g., 96) modulators. If 1536 well plates areused, then a single plate can easily assay from about 100 to about 1500different compounds. It is possible to assay several different platesper day; assay screens for up to about 6,000-20,000 or more differentcompounds are possible using the integrated systems of the invention. Inaddition, microfluidic approaches to reagent manipulation can be used.

A molecule of interest (e.g., a polypeptide or polynucleotide, or amodulator thereof) can be bound to the solid-state component, directlyor indirectly, via covalent or non-covalent linkage, e.g., via a tag.The tag can be any of a variety of components. In general, a moleculethat binds the tag (a tag binder) is fixed to a solid support, and thetagged molecule of interest is attached to the solid support byinteraction of the tag and the tag binder.

The invention provides in vitro assays for identifying, in a highthroughput format, compounds that can modulate the expression oractivity of the genes or polypeptides of the invention. Controlreactions that measure polypeptide activity in a cell in a reaction thatdoes not include a potential modulator are optional, as the assays arehighly uniform. Such optional control reactions are appropriate andincrease the reliability of the assay. Accordingly, in some embodiments,the methods of the invention include such a control reaction. For eachof the assay formats described, “no modulator” control reactions that donot include a modulator provide a background level of binding activity.

VI. Pharmaceutical Formulation and Administration

The compositions of the invention can be administered directly to amammalian subject (e.g., a human) using any route known in the art,including e.g., by injection (e.g., intravenous, intraperitoneal,subcutaneous, intramuscular, or intrademal), inhalation, transdermalapplication, rectal administration, or oral administration.

The pharmaceutical compositions of the invention may comprise apharmaceutically acceptable carrier. Pharmaceutically acceptablecarriers are determined in part by the particular composition beingadministered, as well as by the particular method used to administer thecomposition. Accordingly, there are a wide variety of suitableformulations of pharmaceutical compositions of the present invention(see, e.g., Remington's Pharmaceutical Sciences, 17th ed., 1989).

Formulations suitable for administration include aqueous and non-aqueoussolutions, isotonic sterile solutions, which can contain antioxidants,buffers, bacteriostats, and solutes that render the formulationisotonic, and aqueous and non-aqueous sterile suspensions that caninclude suspending agents, solubilizers, thickening agents, stabilizers,and preservatives. In the practice of this invention, compositions canbe administered, for example, orally, nasally, topically, intravenously,intraperitoneally, or intrathecally. The formulations of compounds canbe presented in unit-dose or multi-dose sealed containers, such asampoules and vials. Solutions and suspensions can be prepared fromsterile powders, granules, and tablets of the kind previously described.The modulators can also be administered as part a of prepared food ordrug.

Formulations suitable for oral administration can comprise: (a) liquidsolutions, such as an effective amount of the packaged nucleic acidsuspended in diluents, such as water, saline or PEG 400; (b) capsules,sachets or tablets, each containing a predetermined amount of the activeingredient, as liquids, solids, granules or gelatin; (c) suspensions inan appropriate liquid; and (d) suitable emulsions. Tablet forms caninclude one or more of lactose, sucrose, mannitol, sorbitol, calciumphosphates, corn starch, potato starch, microcrystalline cellulose,gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearicacid, and other excipients, colorants, fillers, binders, diluents,buffering agents, moistening agents, preservatives, flavoring agents,dyes, disintegrating agents, and pharmaceutically compatible carriers.Lozenge forms can comprise the active ingredient in a flavor, e.g.,sucrose, as well as pastilles comprising the active ingredient in aninert base, such as gelatin and glycerin or sucrose and acaciaemulsions, gels, and the like containing, in addition to the activeingredient, carriers known in the art.

The dose administered to a patient, in the context of the presentinvention should be sufficient to effect a beneficial response in thesubject over time, e.g., at least a reduction of prostate cancer cellgrowth, proliferation or metastasis. The optimal dose level for anypatient will depend on a variety of factors including the efficacy ofthe specific modulator employed, the age, body weight, physicalactivity, and diet of the patient, on a possible combination with otherdrugs, and on the cancer. The size of the dose also will be determinedby the existence, nature, and extent of any adverse side-effects thataccompany the administration of a particular compound or vector in aparticular subject.

VII. Kits

For use in diagnostic, and research applications described above, kitsare also provided by the invention. The kits of the invention maycomprise any or all of the reagents to perform the methods describedherein. In the diagnostic and research applications such kits mayinclude any or all of the following: assay reagents, buffers, nucleicacids that bind to at least one of the genomic regions or genesdescribed herein, hybridization probes and/or primers, antibodies orother moieties that specifically bind to at least one of thepolypeptides encoded by the genes described herein, etc.

In addition, the kits may include instructional materials containingdirections (i.e., protocols) for the practice of the methods of thisinvention. While the instructional materials typically comprise writtenor printed materials they are not limited to such. Any medium capable ofstoring such instructions and communicating them to an end user iscontemplated by this invention. Such media include, but are not limitedto electronic storage media (e.g., magnetic discs, tapes, cartridges,chips), optical media (e.g., CD ROM), and the like. Such media mayinclude addresses to internet sites that provide such instructionalmaterials.

EXAMPLES Example 1

Prostate cancer is the most commonly diagnosed non-cutaneous neoplasmamong American males and is the second leading cause of cancer-relateddeath. Prostate specific antigen (PSA) screening has resulted in earlierdisease detection yet roughly 30% of men will die of metastatic disease.Slow disease progression, an aging population, and associated morbidityand mortality underscore the need for improved disease classificationand therapies. To address these issues, we analyzed a cohort of patientsusing array comparative genomic hybridization (aCGH). The cohort iscomprised of 64 patients half of whom recurred postoperatively. Analysisof the aCGH profiles revealed numerous recurrent genomic copy numberaberrations. Specific loss at 8p23.2 was associated with advanced stagedisease and gain at 11q 13.1 was found to be predictive of postoperativerecurrence independent of stage and grade. Moreover, comparison with anindependent set of metastases revealed ˜40 candidate markers associatedwith metastatic potential. Copy number aberrations at these loci definemetastatic genotypes.

The development of array comparative genomic hybridization (aCGH) hasimportant implications for analysis of tumor genomes as well as fordevelopment of predictive biomarkers and identification of genesinvolved in tumor progression. aCGH allows very high resolutionquantitative detection of copy number aberrations in tumor genomes(Bruder, C. E., Hirvela, C., Tapia-Paez, I., Fransson, I., Segraves, R.,Hamilton, G., Zhang, X. X., Evans, D. G., Wallace, A. J., Baser, M. E.et al. (2001) High resolution deletion analysis of constitutional DNAfrom neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum.Mol. Genet., 10:271-282; Hui, A. B., Lo, K. W., Teo, P. M., To, K. F.and Huang, D. P. (2002) Genome wide detection of oncogene amplificationsin nasopharyngeal carcinoma by array based comparative genomichybridization. Int. J. Oncol., 20:467-473; Hui, A. B., Lo, K. W., Yin,X. L., Poon, W. S. and Ng, H. K. (2001) Detection of multiple geneamplifications in glioblastoma multiforme using array-based comparativegenomic hybridization. Lab. Invest., 81:717-723; Pinkel, D., Segraves,R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo, W.L., Chen, C., Zhai, Y. et al. (1998) High resolution analysis of DNAcopy number variation using comparative genomic hybridization tomicroarrays. Nat. Genet., 20:207-211; Veltman, J. A., Fridlyand, J.,Pejavar, S., Olshen, A. B., Korkola, J. E., DeVries, S., Carroll, P.,Kuo, W. L., Pinkel, D., Albertson, D. et al. (2003) Array-basedcomparative genomic hybridization for genome-wide screening of DNA copynumber in bladder tumors. Cancer Res., 63:2872-2880; Snijders, A. M.,Nowee, M. E., Fridlyand, J., Piek, J. M., Dorsman, J. C., Jain, A. N.,Pinkel, D., van Diest, P. J., Verheijen, R. H. and Albertson, D. G.(2003) Genome-wide-array-based comparative genomic hybridization revealsgenetic homogeneity and frequent copy number increases encompassingCCNE1 in fallopian tube carcinoma. Oncogene, 22:4281-4286); moreover,associations with clinical outcome can be made (Wilhelm, M., Veltman, J.A., Olshen, A. B., Jain, A. N., Moore, D. H., Presti, J. C., Jr.,Kovacs, G. and Waldman, F. M. (2002) Array-based comparative genomichybridization for the differential diagnosis of renal cell cancer.Cancer Res., 62:957-960). Recurrent copy number changes reveal lociencoding tumor suppressors and oncogenes, the identification of which isnow facilitated by completion of the human genome sequence and animpressive repertoire of genome annotation tools (Volik, S., Zhao, S.,Chin, K., Brebner, J. H., Hemdon, D. R., Tao, Q., Kowbel, D., Huang, G.,Lapuk, A., Kuo, W. L. et al. (2003) End-sequence profiling:sequence-based analysis of aberrant genomes. Proc. Natl. Acad. Sci.U.S.A., 100: 7696-7701; Kent, W. J., Sugnet, C. W., Furey, T. S.,Roskin, K. M., Pringle, T. H., Zahler, A. M. and Haussler, D. (2002) Thehuman genome browser at UCSC. Genome Res., 12:996-1006).

The arrays used in this study contain ˜2400 BAC clones and have anaverage genome-wide resolution of 1.4 Mb (Snijders, A. M., Nowak, N.,Segraves, R., Blackwood, S., Brown, N., Conroy, J., Hamilton, G.,Hindle, A. K., Huey, B., Kimura, K. et al. (2001) Assembly ofmicroarrays for genome-wide measurement of DNA copy number. Nat. Genet.,29:263-264; Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I.,Kowbel, D., Collins, C., Kuo, W. L., Chen, C., Zhai, Y. et al. (1998)High resolution analysis of DNA copy number variation using comparativegenomic hybridization to microarrays. Nat. Genet., 20:207-211). Tomaximize the clinical utility of data collected from aCGH experiments,clinical specimens are obtained from patients with substantialfollow-up. Thus, we developed a methodology for performing aCGH with DNAextracted from archived prostate tumors that were formalin-fixed andparaffin-embedded (Paris, P. L., Albertson, D. G., Alers, J. C., Andaya,A., Carroll, P., Fridlyand, J., Jain, A. N., Kamkar, S., Kowbel, D.,Krijtenburg, P. J. et al. (2003) High-resolution analysis ofparaffin-embedded and formalin-fixed prostate tumors using comparativegenomic hybridization to genomic microarrays. Am J Pathol, 162:763-770).To limit the impact of tumor heterogeneity on the sensitivity ofaberration detection, we used a novel tumor microdissection method(Paris, P. L., Albertson, D. G., Alers, J. C., Andaya, A., Carroll, P.,Fridlyand, J., Jain, A. N., Kamkar, S., Kowbel, D., Krijtenburg, P. J.et al. (2003) High-resolution analysis of paraffin-embedded andformalin-fixed prostate tumors using comparative genomic hybridizationto genomic microarrays. Am J Pathol, 162:763-770) and tumor specificsignal thresholding (see Materials and Methods).

In the current study, aCGH was used to analyze 64 tumors from men atintermediate to high risk of recurrence following radical prostatectomy.This cohort is comprised of 32 patients who biochemically progressedfollowing prostatectomy and 32 who did not. Rising PSA followingprostatectomy was used as a biochemical marker of disease recurrence.This unique cohort has a median clinical follow-up of 11 years fornon-progressors (ranging from 8 to 15 years), which is longer than thetime to recurrence for all progressors (ranging from <1 to 8 years),thereby increasing our confidence in outcome classification.

Our previous work demonstrated that analysis of archived prostate tissueby aCGH is capable of detecting single copy changes (Paris, P. L.,Albertson, D. G., Alers, J. C., Andaya, A., Carroll, P., Fridlyand, J.,Jain, A. N., Kamkar, S., Kowbel, D., Krijtenburg, P. J. et al. (2003)High-resolution analysis of paraffin-embedded and formalin-fixedprostate tumors using comparative genomic hybridization to genomicmicroarrays. Am J Pathol, 162:763-770). In the present study, aCGH wasperformed to identify genomic profiles capable of distinguishingindolent from aggressive tumors and loci linked to tumor progression.Because aCGH is performed on arrayed BAC clones with known genome“addresses”, it is theoretically possible to identify multiple BAC-basedmarkers of disease progression (Wilhelm, M., Veltman, J. A., Olshen, A.B., Jain, A. N., Moore, D. H., Presti, J. C., Jr., Kovacs, G. andWaldman, F. M. (2002) Array-based comparative genomic hybridization forthe differential diagnosis of renal cell cancer. Cancer Res.,62:957-960; O'Hagan, R. C., Brennan, C. W., Strahs, A., Zhang, X.,Kannan, K., Donovan, M., Cauwels, C., Sharpless, N. E., Wong, W. H. andChin, L. (2003) Array Comparative Genome Hybridization for TumorClassification and Gene Discovery in Mouse Models of Malignant Melanoma.Cancer Res., 63:5352-5356; Albertson, D. G. and Pinkel, D. (2003)Genomic microarrays in human genetic disease and cancer. Hum. Mol.Genet., 12 Suppl 2:R145-152; Massion, P. P., Kuo, W. L., Stokoe, D.,Olshen, A. B., Treseler, P. A., Chin, K., Chen, C., Polikoff, D., Jain,A. N., Pinkel, D. et al. (2002) Genomic copy number analysis ofnon-small cell lung cancer using array comparative genomichybridization: implications of the phosphatidylinositol 3-kinasepathway. Cancer Res., 62:3636-3640; Omtoft, T. F., Thykjaer, T.,Waldman, F. M., Wolf, H. and Celis, J. E. (2002) Genome-wide study ofgene copy numbers, transcripts, and protein levels in pairs ofnon-invasive and invasive human transitional cell carcinomas. Mol. CellProteomics, 1:37-45).

To extend this study, we included an independent set of metastases in anexploratory exercise to determine whether markers present in primarytumors might be predictive of occult metastasis or proclivity formetastasis. In addition, their inclusion allows identification of knowncancer related genes and/or novel genes that may play a direct role inmetastasis, and may aid in defining new therapeutic approaches. Finally,an ability to compare patterns of recurrent copy number changes innonrecurring primary tumors, primary tumors that metastasize, andmetastatic tumors may provide important insights into the evolution ofprostate cancer.

Results:

Recurrent Copy Number Aberrations

Tumor based thresholds were calculated for all samples. Theoretically alog₂ratio of 0.5 represents a single copy gain and a log₂ratio of −1corresponds to loss of one copy. However, a number of factors impact onthis theoretical value that include the amount of contaminating normaltissue and stroma. The log₂ratio thresholds ranged from an absolutevalue cut-off of 0.19 to 0.52, with an average of 0.34. A subset of 10samples was also analyzed with CGH to metaphase chromosomes, and the twotechniques were concordant.

The overall frequency of copy number changes in the cohort of 64 primarytumors was determined. The most frequent gains (>40%) in both groupsinclude 11p15.4 (66%), 2p25.1 (60%), 13q34 (60%), 11q13.1 (52%), and2p22.1 (45%). Frequently (>40%) lost loci were 8p21.2 (46%) and 8p23.2(45%). Based on the July 2003 freeze of the UCSC human genome browser(http://genome.ucsc.edu/cgi-bin/hgGateway), the genomic position ofthese copy number aberrations correspond to: 2p22 (37891432-39128299),2p25 (9619095-11073793), 11p15 (9238525-11610583), 11q13(63810754-66394362), 13q34 (109071421-111904343),8p21.219764266-25211627), 8p23 (2080710-4357590).

As expected, tumors that progressed had significantly more aberrations(Wilcoxon rank sum p-value p=0.006) than those that did not. The medianvalue for the aberrations for the non-progressors was 10.5 (range 1-56)and 20.5 for progressors (range 1-90). BAC clones that differed by >10%in their frequency of copy number gain or loss between the progressorsand non-progressors were identified.

Deletion of 8p23 is Associated with Advanced Stage

Deletion of 8p23 was more common in progressors than in non-progressors(50% versus 31%). An association was found between pathological advancedstage disease (pT>3) and loss of 8p (p=0.0015). A possible homozygousloss was seen for BAC RP11-112F7 on 8p23.2 (UCSC July 2003 freeze:3284324-3324954). The deletion with the greatest magnitude correspondedto a log2ratio of −0.670. The minimal region of loss is ˜1 Mb andoverlaps exons 3 through 11 of the CUB and Sushi multiple domains 1(CSMD1) gene. A TaqMan primer-probe set was designed for CSMD1. On apanel of 8 RNAs (6 pT2, 2 pT3) from a separate cohort of prostatectomypatients, CSMD1 showed a marked decrease in expression for the patientsof higher stage (pT>3) disease. See FIG. 1.

Gain at 11q13.1 Predicts Recurrence Independent of Stage and Grade

Univariate analysis indicated a statistically significant associationwith BAC CTD-222019 on 11 q13.1 (UCSC July 2003 freeze:64313688-64470546) and biochemical failure status, p<0.002. Thisassociation was even stronger in the subgroup of 39 samples withnegative surgical resection margins. Importantly, the 11q13.1 biomarkerretained its significance when adjusted for the clinical parameters(grade, stage, age at operation, margin and preoperative PSA).Distribution of the log₂ratios for that clone in the negative margincases is shown for progressors and non-progressors in FIG. 2.

The minimal region of the 11q13 amplicon is ˜600 kb. This region of thegenome is gene rich (17 genes and 4790 ESTs represented in 53 Unigeneclusters). The candidate genes that overlap with BAC CTD-222019 areMAP4K2 (mitogen-activated protein kinase kinase kinase kinase 2), MEN1(multiple endocrine neoplasia I), SF1 (splicing factor 1), PPP2R5B(protein phosphatase 2, regulatory subunit B (B56), beta isoform),NAALADASEL (N-acetylated alpha-linked acidic dipeptidase-like) and EHD1(EH-domain containing 1). The newly available Oncomine cancer expressiondatabase was queried for each of these 6 genes to prioritize candidategenes (Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally,R., Ghosh, D., Barrette, T., Pandey, A. and Chinnaiyan, A. M. ONCOMINE:A Cancer Microarray Database and Data-Mining Platform. Neoplasia, inpress). There was no difference in SF1 and EHD1 expression levels forradical prostatectomy patients based on PSA recurrence (Singh, D.,Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo,P., Renshaw, A. A., D'Amico, A. V., Richie, J. P. et al. (2002) Geneexpression correlates of clinical prostate cancer behavior. Cancer Cell,1:203-209). In primary and metastatic tumors, there was no difference inexpression for NAALADASEL and a decrease in PPP2R5B expression formetastatic tumors was observed (Ramaswamy, S., Tamayo, P., Rifkin, R.,Mukherjee, S., Yeang, C. H., Angelo, M., Ladd, C., Reich, M., Latulippe,E., Mesirov, J. P. et al. (2001) Multiclass cancer diagnosis using tumorgene expression signatures. Proc. Natl. Acad. Sci. U.S.A.,98:15149-15154; LaTulippe, E., Satagopan, J., Smith, A., Scher, H.,Scardino, P., Reuter, V. and Gerald, W. L. (2002) Comprehensive geneexpression analysis of prostate cancer reveals distinct transcriptionalprograms associated with metastatic disease. Cancer Res., 62:4499-4506).Only MEN1 and MAP4K2 showed a trend towards an increase in expressionfor progressors versus non-progressors (Dhanasekaran, S. M., Barrette,T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J.,Rubin, M. A. and Chinnaiyan, A. M. (2001) Delineation of prognosticbiomarkers in prostate cancer. Nature, 412:822-826). Real-timeexpression analysis was performed for both MEN1 and MAP4K2. On a panelof 10 RNAs from a separate set of radical prostatectomy patients, onlyMEN1 showed increased expression (FIG. 3). Four of the five cases whereMEN1 was upregulated also showed an increase in copy number at 11q13 byaCGH. In one tumor MEN1 was overexpressed despite normal copy number.

Identification of Candidate Markers of Metastasis

The clinical information for the progressors consisted of recurrencetype, which led us to look for BAC-based predictors of distantmetastases. A set of organ metastases was used to identify copy numberchanges that confer a more aggressive phenotype on primary tumors. FIG.5 shows the result of the analysis of copy number changes in primarytumors that ultimately metastasized and organ metastases versusnon-progressors. Only those BAC clones with a p-value of 0.05 or lessbetween primary tumors that metastasized, organ metastases, andnon-progressing primary tumors are shown. Approximately forty loci wereidentified that were infrequently (0%-20%) altered in primary tumorsthat did not progress. In contrast, aberrations at these loci werefrequent in primary tumors that metastasized (20%-45%) and organmetastases (20%-90%). It is noteworthy that six BAC clones were neveraberrant in the non-progressor cohort (N_(max)=32) but were (20-30%) inboth metastatic cohorts.

Discussion:

To maximize both biological information and clinical correlates, tumorbased thresholds were used for the determination of aCGH gains andlosses. Using spot checks, we confirmed that samples with the smallestthreshold corresponded to aCGH data with extremely good signal to noiseand vice versa for the sample with the largest threshold value. Thetumor based threshold method allowed data with varying signal to noiseratios to be compared to one another. It should be noted that when a BACwas gained in one cohort it was rarely seen to also be deleted in thesame cohort. This demonstrates the good signal to noise obtained withour whole genome aCGH technique.

Previously reported and frequently changed loci in prostate cancer+2p22.1 (Cher, M. L., Bova, G. S., Moore, D. H., Small, E. J., Carroll,P. R., Pin, S. S., Epstein, J. I., Isaacs, W. B. and Jensen, R. H.(1996) Genetic alterations in untreated metastases andandrogen-independent prostate cancer detected by comparative genomichybridization and allelotyping. Cancer Res., 56:3091-3102), +11q13.1 (ElGedaily, A., Bubendorf, L., Willi, N., Fu, W., Richter, J., Moch, H.,Mihatsch, M. J., Sauter, G. and Gasser, T. C. (2001) Discovery of newDNA amplification loci in prostate cancer by comparative genomichybridization. Prostate, 46:184-190), −8p21.2 (Swalwell, J. I., Vocke,C. D., Yang, Y., Walker, J. R., Grouse, L., Myers, S. H., Gillespie, J.W., Bostwick, D. G., Duray, P. H., Linehan, W. M. et al. (2002)Determination of a minimal deletion interval on chromosome band 8p21 insporadic prostate cancer. Genes Chromosomes Cancer, 33:201-205), −8p21.3(Oba, K., Matsuyama, H., Yoshihiro, S., Kishi, F., Takahashi, M.,Tsukamoto, M., Kinjo, M., Sagiyama, K. and Naito, K. (2001) Two putativetumor suppressor genes on chromosome arm 8p may play different roles inprostate cancer. Cancer Genet. Cytogenet., 124:20-26) and −8p23.2(Washburn, J. G., Wojno, K. J., Dey, J., Powell, I. J. and Macoska, J.A. (2000) 8pter-p23 deletion is associated with racial differences inprostate cancer outcome. Clin. Cancer Res., 6, 4647-4652) were alsoidentified in this study, and often at higher resolution. Generally, theprogressors exhibited a higher frequency of change for these loci. Newlydefined amplicons in prostate tumors include 2p25.1, 11p15.4 and 13q34.We observed the expected wide range of inter-tumor heterogeneity in copynumber aberration size at these loci. This phenomenon is well known andmay reflect utilization of different fragile sites, independentmechanisms of aberration formation, and/or biological selection. In thisstudy BAC clones at the 8p23 deletion and 11q13 gain were identifiedcomputationally as having associations with the clinical phenotypes oftumor stage and recurrence, respectively. Individual chromosome specificprofiles were then used to define minimum recurrent aberrationsidentifying MEN1 and CSMD1.

Deletions along 8p are common in prostate cancer (Swalwell, J. I.,Vocke, C. D., Yang, Y., Walker, J. R., Grouse, L., Myers, S. H.,Gillespie, J. W., Bostwick, D. G., Duray, P. H., Linehan, W. M. et al.(2002) Determination of a minimal deletion interval on chromosome band8p21 in sporadic prostate cancer. Genes Chromosomes Cancer, 33:201-205;Oba, K., Matsuyama, H., Yoshihiro, S., Kishi, F., Takahashi, M.,Tsukamoto, M., Kinjo, M., Sagiyama, K. and Naito, K. (2001) Two putativetumor suppressor genes on chromosome arm 8p may play different roles inprostate cancer. Cancer Genet. Cytogenet., 124:20-26; Washburn, J. G.,Wojno, K. J., Dey, J., Powell, I. J. and Macoska, J. A. (2000) 8pter-p23deletion is associated with racial differences in prostate canceroutcome. Clin. Cancer Res., 6, 4647-4652). Whole arm deletion of 8pstrongly associated with higher pathologic stage disease in our study.In a recent prostate study, 8p was found to be the most valuablepredictor of stage (Chu, L. W., Troncoso, P., Johnston, D. A. and Liang,J. C. (2003) Genetic markers useful for distinguishing betweenorgan-confined and locally advanced prostate cancer. Genes ChromosomesCancer, 36:303-312). Our findings confirm and extend these previousstudies.

The identified 8p biomarkers will aid in therapy determination at thetime of a biopsy. The deleted 8p23 BAC clones on the genomic arrayoverlap with a single gene called CSMD1 (Sun, P. C., Uppaluri, R.,Schmidt, A. P., Pashia, M. E., Quant, E. C., Sunwoo, J. B., Gollin, S.M. and Scholnick, S. B. (2001) Transcript map of the 8p23 putative tumorsuppressor region. Genomics, 75:17-25; Toomes, C., Jackson, A., Maguire,K., Wood, J., Gollin, S., Ishwad, C., Paterson, I., Prime, S.,Parkinson, K., Bell, S. et al. (2003) The presence of multiple regionsof homozygous deletion at the CSMD1 locus in oral squamous cellcarcinoma question the role of CSMD1 in head and neck carcinogenesis.Genes Chromosomes Cancer, 37:132-140). This is the first report of CSMD1undergoing deletion in prostate cancer. This finding is supported byprostate cancer expression microarray experiments that found CSMD1decreased expression to be associated with relapse and survival(Henshall, S. M., Afar, D. E., Hiller, J., Horvath, L. G., Quinn, D. I.,Rasiah, K. K., Gish, K., Willhite, D., Kench, J. G., Gardiner-Garden, M.et al. (2003) Survival analysis of genome-wide gene expression profilesof prostate cancers identifies new prognostic targets of diseaserelapse. Cancer Res., 63:4196-4203). Sushi domains exist in adhesionproteins, and therefore make CSMD1 a likely target for deletion by anaggressive tumor. In a recent aCGH study of 14 fallopian tumors, 12tumors showed deletion involving the CSMD1 region (Snijders, A. M.,Nowee, M. E., Fridlyand, J., Piek, J. M., Dorsman, J. C., Jain, A. N.,Pinkel, D., van Diest, P. J., Verheijen, R. H. and Albertson, D. G.(2003) Genome-wide-array-based comparative genomic hybridization revealsgenetic homogeneity and frequent copy number increases encompassingCCNE1 in fallopian tube carcinoma. Oncogene, 22:4281-4286). The minimalregion of recurrent loss in their study directly overlapped ours(RP11-82K8 to RP11-140K14). TaqMan results, in a separate cohort ofpatients, provided further evidence for a decrease in CSMD1 expressionin higher stage (pT≧3) prostate tumors. In addition to being a marker ofadvanced stage disease, deletion of 8p23.2 may be a marker of diseaserecurrence and therefore warrants future studies. There is considerableevidence implicating the NKX3.1 gene at 8p21 as a tumor suppressor genein prostate cancer (Xu, L. L., Srikantan, V., Sesterhenn, I. A.,Augustus, M., Dean, R., Moul, J. W., Carter, K. C. and Srivastava, S.(2000) Expression profile of an androgen regulated prostate specifichomeobox gene NKX3.1 in primary prostate cancer. J. Urol., 163:972-979;Bhatia-Gaur, R., Donjacour, A. A., Sciavolino, P. J., Kim, M., Desai,N., Young, P., Norton, C. R., Gridley, T., Cardiff, R. D., Cunha, G. R.et al. (1999) Roles for Nk×3.1 in prostate development and cancer. GenesDev., 13:966-977; He, W. W., Sciavolino, P. J., Wing, J., Augustus, M.,Hudson, P., Meissner, P. S., Curtis, R. T., Shell, B. K., Bostwick, D.G., Tindall, D. J. et al. (1997) A novel human prostate-specific,androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a regionfrequently deleted in prostate cancer. Genomics, 43:69-77). CSMD1 andNKX3.1 map ˜18 Mb apart in noncontiguous deletions, and thus representindependent tumor suppressor genes.

Previous studies have identified loci that associate with aggressivebehavior for prostate cancer (Neville, P. J., Conti, D. V., Krumroy, L.M., Catalona, W. J., Suarez, B. K., Witte, J. S. and Casey, G. (2003)Prostate cancer aggressiveness locus on chromosome segment 19q12-q13.1identified by linkage and allelic imbalance studies. Genes ChromosomesCancer, 36:332-339; Neville, P. J., Conti, D. V., Paris, P. L., Levin,H., Catalona, W. J., Suarez, B. K., Witte, J. S. and Casey, G. (2002)Prostate cancer aggressiveness locus on chromosome 7q32-q33 identifiedby linkage and allelic imbalance studies. Neoplasia, 4:424-431; Witte,J. S., Goddard, K. A., Conti, D. V., Elston, R. C., Lin, J., Suarez, B.K., Broman, K. W., Burmester, J. K., Weber, J. L. and Catalona, W. J.(2000) Genomewide scan for prostate cancer-aggressiveness loci. Am. J.Hum. Genet., 67:92-99; Takahashi, S., Shan, A. L., Ritland, S. R.,Delacey, K. A., Bostwick, D. G., Lieber, M. M., Thibodeau, S. N. andJenkins, R. B. (1995) Frequent loss of heterozygosity at 7q31.1 inprimary prostate cancer is associated with tumor aggressiveness andprogression. Cancer Res., 55:4114-4119; Elo, J. P., Harkonen, P.,Kyllonen, A. P., Lukkarinen, O., Poutanen, M., Vihko, R. and Vihko, P.(1997) Loss of heterozygosity at 16q24.1-q24.2 is significantlyassociated with metastatic and aggressive behavior of prostate cancer.Cancer Res., 57:3356-3359; Alers, J. C., Rochat, J., Krijtenburg, P. J.,Hop, W. C., Kranse, R., Rosenberg, C., Tanke, H. J., Schroder, F. H. andvan Dekken, H. (2000) Identification of genetic markers for prostaticcancer progression. Lab Invest., 80:931-942; Alers, J. C., Krijtenburg,P. J., Vis, A. N., Hoedemaeker, R. F., Wildhagen, M. F., Hop, W. C., vanDer Kwast, T. T., Schroder, F. H., Tanke, H. J. and van Dekken, H.(2001) Molecular cytogenetic analysis of prostatic adenocarcinomas fromscreening studies: early cancers may contain aggressive geneticfeatures. Am. J. Pathol., 158:399-406); however, very few genes havebeen identified to date. Amplifications on 11q13 have been reported inother cancers (Kusano, N., Okita, K., Shirahashi, H., Harada, T.,Shiraishi, K., Oga, A., Kawauchi, S., Furuya, T. and Sasaki, K. (2002)Chromosomal imbalances detected by comparative genomic hybridization areassociated with outcome of patients with hepatocellular carcinoma.Cancer, 94:746-751; Brookes, S., Lammie, G. A., Schuuring, E., de Boer,C., Michalides, R., Dickson, C. and Peters, G. (1993) Amplified regionof chromosome band 11q13 in breast and squamous cell carcinomasencompasses three CpG islands telomeric of FGF3, including the expressedgene EMS 1. Genes Chromosomes Cancer, 6:222-231; Fantl, V., Richards, M.A., Smith, R., Lammie, G. A., Johnstone, G., Allen, D., Gregory, W.,Peters, G., Dickson, C. and Barnes, D. M. (1990) Gene amplification onchromosome band 11q13 and oestrogen receptor status in breast cancer.Eur. J. Cancer, 26:423-429; Lammie, G. A., Fantl, V., Smith, R.,Schuuring, E., Brookes, S., Michalides, R., Dickson, C., Arnold, A. andPeters, G. (1991) D11S287, a putative oncogene on chromosome 11q13, isamplified and expressed in squamous cell and mammary carcinomas andlinked to BCL-1. Oncogene, 6:439-444), but rarely in prostate cancer(Kasahara, K., Taguchi, T., Yamasaki, I., Kamada, M., Yuri, K. andShuin, T. (2002) Detection of genetic alterations in advanced prostatecancer by comparative genomic hybridization. Cancer Genet Cytogenet,137:59-63; El Gedaily, A., Bubendorf, L., Willi, N., Fu, W., Richter,J., Moch, H., Mihatsch, M. J., Sauter, G. and Gasser, T. C. (2001)Discovery of new DNA amplification loci in prostate cancer bycomparative genomic hybridization. Prostate, 46:184-190). We havesignificantly narrowed the region on 11q13 identified by El Gedaily andKasahara in advanced prostate cancer case (Kasahara, K., Taguchi, T.,Yamasaki, I., Kamada, M., Yuri, K. and Shuin, T. (2002) Detection ofgenetic alterations in advanced prostate cancer by comparative genomichybridization. Cancer Genet Cytogenet, 137:59-63; El Gedaily, A.,Bubendorf, L., Willi, N., Fu, W., Richter, J., Moch, H., Mihatsch, M.J., Sauter, G. and Gasser, T. C. (2001) Discovery of new DNAamplification loci in prostate cancer by comparative genomichybridization. Prostate, 46:184-190). In our intermediate and high riskof recurrence cohort, we identified a BAC clone mapping to 11q13.1 thatshowed a statistically significant increase in copy number in tumorsfrom patients who failed following radical prostatectomy as compared tothose who did not recur and that was an independent predictor ofrecurrence. MEN1 maps to this locus and recent prostate cancer geneexpression profiling experiments identified elevated expression of MEN1to be associated with recurrence (Lapointe, J., Li, C., Higgins, J. P.,van de Rijn, M., Bair, E., Montgomery, M., Ferrari, M., Egevad, L.,Rayford, W., Bergerheim, U. et al. (2004) Gene expression profilingidentifies clinically relevant subtypes of prostate cancer. Proc. Natl.Acad. Sci. U.S.A., 101:811-816). Our real-time expression analysis onRNAs from prostatectomy patients showed an increase in expression forMEN1 for several cases, all but one exhibited corresponding genomic gainfor the 11q13 locus. The exception is interesting because it impliesmechanisms independent of amplification can result in increased MEN1expression in prostate cancer. There was no correlation betweenincreased expression and stage or grade, possibly indicating that thismarker acts independent of those clinical parameters.

Genes that have been implicated in pathways involving prostate cancerwere also found to lie in regions of genomic gain and loss in thisstudy. The oncogene MYC showed genomic gain in the progressors, and atan even higher frequency in the metastatic cohort, as compared to thenon-progressors. The tumor suppressor RB1 was shown to be morefrequently deleted in the progressors, and at an even a higher frequencyin the metastatic tumors than the non-progressors. Apoptosis of prostatecancer cells wild type for Rb has been shown to occur by means of anintracellular pathway that involves the activation of Rb and repressionof MYC transcription (Zhao, X. and Day, M. L. (2001) RB activation andrepression of C-MYC transcription precede apoptosis of human prostateepithelial cells. Urology, 57:860-865). We observed that the combinationof +8q24.21/−13q14.2 occurred in 40% of the metastases.

Recent work in the gene expression field reported that a subset ofprimary solid tumors share the gene expression signature of theircorresponding organ metastases (Ramaswamy, S., Ross, K. N., Lander, E.S. and Golub, T. R. (2003) A molecular signature of metastasis inprimary solid tumors. Nat. Genet., 33:49-54). We propose that genomicchanges in metastatic tumors can guide identification of the mostimportant genomic changes in primary tumors. This should be especiallyuseful in slow growing, highly heterogeneous tumors, such as prostatecancer. In addition, prostate cancer cells exhibit very heterogeneousgenomic profiles. Metastatic prostate tumors that have evolved furtherand are more homogenous can help elucidate which genetic changes conferaggressive phenotypes in primary tumors. Pattern recognition analysisidentified a combination of BAC clones that may be utilized asbiomarkers for predicting metastasis at the time of biopsy or surgery,and therefore assist in the identification of patients who would benefitfrom the use of adjuvant therapy. For example, the BAC gained at 22q13.1in FIG. 5A maps to platelet derived growth factor beta, PDGFB. This isintriguing since the receptors for PDGF have been shown to be expressedin advanced prostate cancer (Chott, A., Sun, Z., Morganstern, D., Pan,J., Li, T., Susani, M., Mosberger, I., Upton, M. P., Bubley, G. J. andBalk, S. P. (1999) Tyrosine kinases expressed in vivo by human prostatecancer bone marrow metastases and loss of the type 1 insulin-like growthfactor receptor. Am. J. Pathol., 155:1271-1279). The beta receptor inparticular has recently been shown to serve as a recurrence predictor ina 5-gene model (Singh, D., Febbo, P. G., Ross, K., Jackson, D. G.,Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V.,Richie, J. P. et al. (2002) Gene expression correlates of clinicalprostate cancer behavior. Cancer Cell, 1:203-209). LIMK1 (LIM domainkinase 1), mapping to 7q11.23 in FIG. 5A, has recently been shown to beoverexpressed in prostate tumors and metastatic cell lines (Davila, M.,Frost, A. R., Grizzle, W. E. and Chakrabarti, R. (2003) LIM kinase 1 isessential for the invasive growth of prostate epithelial cells:implications in prostate cancer. J. Biol. Chem., 278:36868-36875). Inthe same report, partial reduction in LIMK1 was shown to abolish themetastatic invasiveness of prostate cells in vitro (Davila, M., Frost,A. R., Grizzle, W. E. and Chakrabarti, R. (2003) LIM kinase 1 isessential for the invasive growth of prostate epithelial cells:implications in prostate cancer. J. Biol. Chem., 278:36868-36875).Additionally, the tumor suppressor PTEN maps to the BAC identified at10q23.1 in the exploratory biomarker analysis shown in FIG. 5B.Prostate-specific deletion of the murine Pten tumor suppressor gene hasbeen shown to lead to metastatic prostate cancer (Wang, S., Gao, J.,Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G.,Roy-Burman, P., Nelson, P. S. et al. (2003) Prostate-specific deletionof the murine Pten tumor suppressor gene leads to metastatic prostatecancer. Cancer Cell, 4:209-221).

A significant strength of aCGH is its ability to expeditiously andquantitatively map both copy number gains and single copy losses atmultiple independent loci in clinical specimens. This study hassignificantly expanded the catalogue of recurrent aberrations found inprostate cancer and this may enable a deepened understanding of itsetiology and progression. Amplification at 11q13.1 is predictive ofpostoperative disease recurrence, deletion at 8p23 is stronglyassociated with advanced disease stage and candidate genes have beenidentified at each locus and these may form the basis for futurediagnostics and therapies pending independent clinical validation.Genomic profiles were obtained from organ metastases and used tointerrogate the genomic profiles of primary tumors for genomeaberrations associated with metastasis. This exploratory analysisyielded a large number (˜40) of biomarkers that define metastaticgenotypes.

Materials and Methods:

Patients

Prostatectomy patients were retrospectively selected from ErasmusUniversity Medical Center in the Netherlands. The cohort consists of 64prostate cancer patients who were either at intermediate or high risk ofrecurrence at diagnosis (D'Amico, A. V., Whittington, R., Malkowicz, S.B., Fondurulia, J., Chen, M. H., Kaplan, I., Beard, C. J., Tomaszewski,J. E., Renshaw, A. A., Wein, A. et al. (1999) Pretreatment nomogram forprostate-specific antigen recurrence after radical prostatectomy orexternal-beam radiation therapy for clinically localized prostatecancer. J. Clin. Oncol., 17:168-172. Following surgery, PSAs weremonitored every 3 months during the first year, bi-annually in the2^(nd) year followed by yearly. 32 of these patients never had abiochemical failure after surgery (PSA<0.2 ng/ml) or any other evidenceof disease recurrence. The median follow-up for the non-progressors was11 years. The other 32 patients failed biochemically. In this study, abiochemical relapse was defined as a) two consecutive PSA serumlevels≧0.2 ng/ml with an interval of at least 3 months followed by anelevated PSA (≧0.2 ng/ml), or b) a single observation of PSA≧1 ng/mlfollowed by an elevated PSA (≧0.2 ng/ml). PSA levels≧0.2 ng/ml occurringin the first three months after radical prostatectomy were notconsidered a biochemical relapse if followed by undetectable (<0.1ng/ml) PSA values. The progression-free survival was defined as theinterval between the time of surgery and the first elevated PSA serumlevel (≧0.2 ng/ml). Other clinical parameters, such as Gleason score,pathological stage, age at operation, pre-operative PSA and surgicalmargin status are listed in Table 1 for the 64 patients (32 progressors,32 non-progressors). TABLE 1 Clinical characteristics of the cohort A.Progressors ProgFree Progress Patient OperYr AgeOper PreOpPSA StageGrade ResMargin Survival Type  1 1991 61 11.2 2a 5 0 91 PSA  2 1992 6323.6 2c 7 0 73 PSA  3 1990 67 64.3 3c 7 1 2 M1b  4 1994 61 23.7 4a 7 126 M1a  5 1988 68 17.1 3c 7 1 3 PSA  6 1991 71 29.6 4a 7 0 44 LR  7 199472 7.1 2c 7 1 23 PSA  8 1988 70 1 4a 7 0 10 LR  9 1988 69 29 3c 7 1 33M1b 10 1993 65 11.8 3a 7 0 52 PSA 11 1986 65 No data 3b 7 1 38 M1b 121987 64 No data 3c 7 1 83 PSA 13 1989 60 6.5 3a 6 0 13 PSA 14 1989 655.5 3c 7 1 37 PSA 15 1990 61 21 3b 7 0 3 LR 16 1991 61 7.8 3a 7 1 71 LR17 1992 66 6.4 3a 7 1 41 PSA 18 1992 70 25.1 4a 7 0 1 PSA 19 1991 69 0.72a 6 0 54 LR + M1b 20 1992 63 18.7 4a 7 1 8 LR + M1b 21 1992 53 16.5 3a7 0 2 LR + M1b 22 1990 55 13.2 4a 7 1 38 LR 23 1990 51 2.8 4a 6 1 16 PSA24 1992 58 108 4a 5 0 5 LR 25 1992 47 11.5 3a 7 0 2 M1b + M1c 26 1992 593.2 3a 7 1 75 M1b 27 1989 59 16.9 4a 7 0 13 M1b 28 1989 74 19.4 3a 7 117 PSA 29 1990 65 25.2 3a 7 1 83 PSA 30 1990 71 16.1 3a 7 0 98 PSA 311991 69 17.8 4a 7 0 4 M1a + M1b + M1c 32 1991 62 73.7 4a 7 1 2 LR + M1bB. Non-progressors Patient OperYr AgeOper PreOpPSA Stage Grade ResMargin33 1990 59 9.2 2b 7 0 34 1990 64 7.4 2b 6 0 35 1991 65 11.1 2c 5 0 361989 60 19.4 3a 7 0 37 1992 59 17.2 2c 7 0 38 1992 51 16.1 2a 7 1 391993 72 12.2 3b 7 1 40 1994 66 9.7 2c 6 1 41 1992 67 4.8 3a 5 1 42 199352 2.2 3a 7 0 43 1993 58 5.8 2c 6 0 44 1987 59 No data 4a 7 1 45 1993 672.2 2c 6 0 46 1994 65 10.6 2c 6 0 47 1993 55 16.4 2c 6 0 48 1994 62 21.52c 6 0 49 1989 62 5.2 3b 7 1 50 1990 59 18.6 3a 7 0 51 1992 65 23.1 4a 70 52 1992 67 2.2 3a 6 0 53 1992 63 4.5 3a 5 0 54 1991 49 21.8 3a 6 0 551991 59 8 3a 6 0 56 1991 70 11.7 2c 7 0 57 1990 69 2.6 4a 5 0 58 1990 612.5 4a 5 0 59 1991 44 17.3 3a 6 0 60 1991 68 13.5 3a 6 0 61 1991 72 15.33a 7 0 62 1991 51 7.5 3a 7 1 63 1991 65 27.8 3b 7 1 64 1991 52 5.6 3a 70Table 1 Legend: OperYr = year of prostatectomy, AgeOper = age of patientat time of surgery, PreOpPSA = preoperative PSA, Res Margin = resectionmargin status, 0 (negative) and 1 (positive), ProgFreeSurvival = lengthof time (months) to biochemical relapse, ProgressType = PSA = no data onlocal or distance recurrence, LR = local recurrence, M1a =#metastasis in non-regional lymph node, M1b = bone metastasis, M1c =other site metastasis. The Gleason Grading system (Gleason, D. F. (1992)Histologic grading of prostate cancer: a perspective. Human Pathology,23: 273-279) and the TNM Classification (Hermanek, P., Hutter, R.V.P.and Sobin, L.H. (1997) TNM Atlas IUAC. 4th Ed ed. New York, Springer)were used. The usage of elevated (0.2 ng/ml or greater) PSA as a firstindicator for imminent # local or distant recurrent disease has beenreported by several authors.

In order to study metastatic tumors, 15 hormone refractory, metastatictumors from the Rapid Autopsy Program from the University of MichiganProstate SPORE were evaluated (Rubin, M. A., Putzi, M., Mucci, N.,Smith, D. C., Wojno, K., Korenchuk, S. and Pienta, K. J. (2000) Rapid(“warm”) autopsy study for procurement of metastatic prostate cancer.Clin. Cancer Res., 6, 1038-1045). 15 tissue slices at 15 microns wereextracted with a Wizard Genomic DNA Isolation kit (Promega, Madison,Wis.) according to the manufacturer's protocol. The DNA was furtherpurified by phenol/chloroform extraction, followed by ethanolprecipitation.

Tissue Processing

All paraffin-embedded formalin fixed prostate tissue blocks were stainedwith DAPI to outline tumor areas. A bore (1 mm-1 cm in diameter)attached to a microscope was used to punch a few millimeters deep intothe selected tumor region. H & E's were performed for the first and thelast slice corresponding to the punch to insure the tumor region wasconsistent from top to bottom.

DNA was extracted using the Puregene DNA isolation kit (Gentra Systems,Minneapolis, Minn.).

aCGH

The human version 2.0 BAC arrays were provided by the UCSF Array Core.Each array consists of 2460 BAC clones spotted in triplicate on chromiumslides. The resolution is approximately 1.4 Mb. The aCGH protocol thatwas followed is detailed in our recent aCGH archived tissue techniquepaper (Paris, P. L., Albertson, D. G., Alers, J. C., Andaya, A.,Carroll, P., Fridlyand, J., Jain, A. N., Kamkar, S., Kowbel, D.,Krijtenburg, P. J. et al. (2003) High-resolution analysis ofparaffin-embedded and formalin-fixed prostate tumors using comparativegenomic hybridization to genomic microarrays. Am J Pathol, 162:763-770).Also included in this reference are details regarding the in-houseimaging system and software that was used to process the arrays.

Table 2 displays the designations of the BACS used to probed the genomiclocations. The table also includes genes identified in or near the BACsas well as sequence information for the BACs The BACs are generallyavailable from Invitrogen, Inc. (Carlsbad, Calif.). TABLE 2 Genbankaccession numbers of DNA BAC Clone Name Locus Genes in or near BACwithin BAC GAINS CTB-172I13 2qtel RP11-1146E5 3q26.2 EVI1 (AF487422)AQ698393 RP11-114M1 3q26.32 IRA1 AC026355.13 RP1-97B16 3q26.3 PIK3CA(3q26.3) STS RH70978 RP11-88L18 5p15.1 BASP1 part of NT_006576,NT_023089 contig, ends of BAC at AQ281504, AQ281510, and AZ516846RP11-23D23 7p22.3 GPR30; UNC84A; MAFK part of NT_079592 contig, STSmarkers SHGC-32510 CTC-329F6 7p22.3 EIF3S9 CL423016 (partial sequence)RP1-117G9 7q11.23 ELN (AK075494); LIMK1 AK075494 (ELN) (AK125511);WBSCR5; RFC2; CYLN2 RP11-96O16 7q11.22 AUTS2 part of NT_079593,NT_007758 contig, ends of BAC at: AQ313616 AQ313618 RP11-213E22 7q22.1VGF, Serpinel, PLOD3, AP1S1 Ends of BAC at: AQ484445 AQ484446CTD-2041G23 7q31.31 CORTBP2 End of BAC at AQ236419 RP11-17O4 9q34.1 ASB6part of NT_008470 contig, End of BAC at: B81878 RP4-693L23 11p15.5 p57(KIP2) WI-17359 (RH marker for KIP2) RP5-1071I14 17q21.33 NGFR D17S797RP11-46E14 17q25.3 CBX4; CBX8; GAA; DDX48 part of NT_024871contig; Endsof BAC at: AQ201028 AQ201029 RMC22P003 22q13.1 PDGFB D22S1108 LOSSESRP11-253O5 4p13 part of NT_006238 contig End of BAC at: STS MarkersSHGC4-344 RP11-267K19 5q13.1 PIK3R1 part of NT_006431 contig End of BACat: STS Markers AFMB281YB9 RP11-135F5 5q14.3 COX7C part of NT_006713contig. End of BAC at: AQ380700 RP11-203J7 5q21.1 PAM part of NT_034772contig End of BAC at: AQ419291 AQ419293 RP11-115L24 5q21.2 PAMAC009815.2 End of BAC at: AQ348041 AQ348042 CTD-2079J2 5q21.3 FER partof NT_034772 contig Ends of BAC at: STS Markers SGC31298 WI-13009STSG39082 WI-6744 RP11-73N22 5q23.1 CG734300, NT_034772 RP11-217L136q14.1 HMGN3 NT_007299, AC027616, Ends of BAC at: STS Markers AFM191XA3AFM191XA3 RP11-28L24 6q21 TUBE1; LAMA4 part of NT_025741 contig Ends ofBAC at: B87392 AQ003445 RP11-47E20 6q21 BVES; POPDC3 part of NT_025741contig Ends of BAC at: AQ199394, AQ199397 RP11-182G2 8p22 TUSC3 part ofNT_030737 contig End of BAC at: STS Marker SHGC- 1961 RP11-76B12 8p21.2DOCK5 part of NT_023666 contig End of BAC at: AQ281843 RP11-232J228p21.2 BNIP3L part of NT_023666 contig End of BAC at: AQ485011CTD-2015D3 8p21.2 ADRA1 part of NT_023666 contig End of BAC at: B54151B65002 AQ226511 AQ236188 RP11-57I3 8p12 NRG1 part of NT_007995 contigEnd of BAC at: AQ082612, AQ115482 RP11-129G17 10q23.31 PTEN AL353149.10RP11-14A4 13q14.11 LHFP part of NT_024524 contig End of BAC at: B81624CTD-2202J2 13q14.11 FOX01A End of BAC at: AQ151331 RP11-17I11 13q14.11part of NT_024524 contig Ends of BAC at: B82714 B82713 RP11-217H2313q14.13 GTF2F2 part of NT_024524 contig End of BAC at: STS Marker SHGC-11937 CTD-2173J2 13q14.2 RB1; CHC1L part of NT_024524 contig Ends of BACat: B94340, B94349 RP1-269F22 13q14.3 D13S25 RP11-12H11 16q23.1 ADAMTS18part of NT_024797 contig. Ends of BAC at: B75800 B75801Statistical Analysis

The tumor:reference fluorescence intensity ratios were converted to thelog₂ domain. The observed log₂ratios were not included if there werefewer than two replicate spots (out of 3) or if the standard deviationof the replicates was above 0.2. Each array was normalized to have amedian log₂ratio of 0. The clones that were present in fewer than 75% ofthe samples (or 48 samples) were removed from the dataset (348 or 13% ofthe clones). 2127 clones remained in the dataset.

To identify the gained and lost clones in individual samples, weconstructed sample-specific thresholds (Fridlyand, J., Snijders, A.,Pinkel, D., Albertson, D. G. and Jain, A. N. (2004) Application ofHidden Markov Models to the analysis of the array CGH data. Journal ofMultivariate Analysis (Special Genomic Issue), in press). The cloneswith log₂ratios above or below +/−a tumor's threshold were consideredgained or lost, respectively. To calculate thresholds, we useddiscrete-time Hidden Markov Model (Rabiner, L. R. (1989) A tutorial onhidden Markov models and selected applications in sppech recognition.Proc. IEEE, 77, 257-286) to segment clones on individual chromosomesinto the states corresponding to underlying copy numbers. The number ofstates was determined with the BIC (Schwarz, G. (1978) Estimating thedimension of a model. The Annals of Statistics, 6, 461-464) criterion.In order to increase robustness of the procedure, we used only thosechromosomes that contained less than 3 different states and only thosestates that contained at least 20 clones. We assumed that experimentalmeasurement error is independent of the underlying copy number. Thus,for each state and chromosome that met the above criteria, we calculatedthe median absolute deviation (MAD) of the log₂ratios of the clones onthat chromosome belonging to a given state. The final estimate of thestandard deviation of the experimental noise, SD, was then calculated asthe median of the above MAD values across all used states andchromosomes. Finally the thresholds were calculated conservatively as2.5 times the SD for a given tumor. The ad-hoc justification for usingthis threshold lies in considering the standard normal distribution(1.2% of the standard normals are expected to exceed the absolutecut-off of 2.5). The frequency of gains and losses for a given clone ina group of interest was calculated as the proportion of samples in whicha clone was gained or lost in that group.

We imputed the missing values (8.8% of the observations) using the KNearest Neighbors (KNN) algorithm (Troyanskaya, O., Cantor, M.,Sherlock, G., Brown, P., Hastie, T., Tibshirani, R., Botstein, D. andAltman, R. B. (2001) Missing value estimation methods for DNAmicroarrays. Bioinformatics, 17:520-525). We computed all pairwisecorrelations among the clones and assign 5 closest neighbors to eachclone (i.e. the clones most highly correlated with a given clone). Then,if a particular clone was missing in a given sample, the missing valuewas replaced by the average of the values of that clone's 5 closestneighbors in that sample. To impute all missing values, we iterated theabove procedure twice using 10 neighbors at the second iteration.

For a given phenotype, we looked for the clones with significantlydifferent underlying copy number between the subtypes. Since the clonesthat rarely show an abnormal copy number are not a priori likely tocontribute to the difference among subgroups, we reduce the multiplicityof the comparisons by only considering the clones that show the gain orloss separately in at least 20% of the samples. There were 122 suchclones, with 35% located on chromosome 8 (almost all on 8p).

To test univariately for association between the copy number and aphenotype, for each clone we tested the null hypothesis that thedistribution of the copy was the same in each of the subgroups, by usinga t-statistic with pooled variance when two groups were being comparedand F-statistic for more than two groups (Snedeckor, G. W. and G., C. W.(1989) In Statistical Methods. 5 ed. University Press, p. Chapter 5).The p-value for a clone was computed by considering the distribution ofthe t-statistic under the null hypothesis of no difference between thetwo groups. An adjustment for multiple comparisons was made so as tolimit the probability of finding at least one false positive result. Inpractice, this was implemented using the maxT method (Westfall, P. H.and Young, S. S. (1993) Resampling-based multiple testing: Examples andmethods for p-value adjustment. Wiley) by randomly permuting thesubgroup labels, recomputing the statistic for each clone and recordingthe maximum absolute value of the statistic over all clones. We repeatedthe procedure 10,000 times. The observed statistic for a given clone wascompared to the distribution of the recorded maxima and the adjustedp-value equal to the proportion of the recorded maximum values exceedingthe absolute observed t-statistic for a given clone.

This patient sample was selected to have a 50% probability ofrecurrence. To determine independent predictors of recurrence, we fitthe multivariate Cox-proportional hazards model using all of theclinical variables and the significant loci identified in the univariateanalysis. All of the statistical analyses were done in the environmentof the freely available statistical package R (Ihaka, R. and Gentleman,R. (1996) R: A language for Data Analysis and Graphics. Journal ofComputational and Graphical Statistics, 5, 299-314).

We looked for BAC clones that could serve as a group to identify tumorswith metastatic potential. The frequency of change for each BAC wascomputed and copy number aberrations that occurred in 20% or more of theprogressors that later metastasized and organ metastases, but less than20% of the non-progressors and vice versa were considered adifferentiating BAC. For each clone the proportion of cases either aboveor below the defined threshold between non-progressors and those withmetastases was compared using Fisher's one-sided exact test.

Validation of Candidate Genes with TaqMan

For validation of candidate genes, RNA was extracted from tumors andbenign tissue obtained from 10 radical prostatectomy specimens andanalyzed using TaqMan RNA quantitation. For each case, this wasperformed as follows. Twenty 13 micron slices were obtained from UCSFcomprehensive Cancer Center fresh-frozen Tissue bank, with the first,tenth and twentieth sections H&E stained for evaluation of tissue typesand amounts. Areas of interest on these slides were then marked to actas guides for microdissecting the areas for analysis from the remainingunstained sections; only areas with greater than 70% of the tissue ofinterest (benign prostate epithelium or tumor) were marked. Theunstained slides were dehydrated using steps of 70%, 90% and 100%ethanol for one minute each followed by immersion in Xylene for 5minutes. After the slides dried, outlined areas were microdissected fromthe slides using a scalpel blade, and the dissected tissue suspendedinto a lysis buffer containing 1% P-mercaptoethanol (RNeasy kit,Qiagen). The tissue was homogenized using a Qiashredder spin column(Qiagen) and the RNA extracted according to manufacturer's suggestions.The RNAs were run on an Agilent 2100 BioAnalyzer (Palo Alto, Calif.) toassess RNA quality. Tissue samples were retained in the study if therewas not any significant RNA degradation.

TaqMan assays were carried out by the UCSF Genome Core. TaqManprimer-probe sets were available as Assays on Demand kits through ABI(Foster City, Calif.) for MAP4K2 and MEN1. The CSMD1 TaqMan primer-probeset was designed in-house and synthesized by IDT (Coralville, Iowa). Theforward primer (5′-TTTCCAGATTTTTATCCAAACTCTCTAA-3′) and probe(5′-FAM-CACGTGGACCATTGAAGTGTCTCATGG-BHQ 1-3′) (BHQ=black hole quencher 1from Biosearch Technologies, Novato, Calif.) lie within exon 19 and thereverse primer (5′-GTGTGAAAGATCATTTGAACTCCTTT-3′) spans exons 19 and 20of CMSD1. Each tissue sample was run in triplicate. Good methodology wasdemonstrated by the standard deviation for the cycle threshold values ofall three replicates being less than 0.3. The prostate tissue sample wasretained in the study if the direction of change in expression for thecandidate gene was the same compared to two reference genes (18S andGUS). Results are displayed as percentage of expression relative to GUS,since similar changes were seen for 18S.

Example 2

Risk assessment and counseling tools used to predict disease outcome inurology include nomograms and risk grouping models. Nomograms are scaledrepresentations of statistical models defined by weighting significantpredictors used to calculate the probability of a disease outcome. Incontrast, risk grouping models use disease associated variables (e.g.,prostate-specific antigen (PSA), Gleason grade, clinical stage) toassign outcome categories (e.g., high-risk, low-risk). Two of the mostwidely-used risk assessment tools currently available to predictbiochemical failure after radical prostatectomy are a three-levelcategorization published by D'Amico et al. (D'Amico A V, Whittington R,Malkowicz S B, et al. JAMA 1998;280(11):969-74) and a continuousnomogram devised by Kattan et al. (Kattan M W, Eastham J A, Stapleton AM, Wheeler T M, Scardino P T. J Natl Cancer Inst 1998;90(10):766-71).Nomograms have better predictive accuracy than some extant risk groupingmodels (Kattan M W, Zelefsky M J, Kupelian P A, Scardino P T, Fuks Z,Leibel S A. J Clin Oncol 2000;18(19):3352-9; Kattan M W, Heller G,Brennan M F. Stat Med 2003;22(22):3515-25) and are superior to expertassessment. The Kattan nomogram predicts outcome for higher riskpatients better than other existing nomograms. These tools areconvenient, useful for patient counseling and decision making, andapplicable for use in clinical trials. However, the concordance ratesfor these nomograms and actual pathologic stage or recurrenceapproximate 68% (Ross P L, Scardino P T, Kattan M W. A catalog ofprostate cancer nomograms. J Urol 2001;165(5):1562-8). These instrumentscould be improved by adding phenotypic or genotypic markers as acomponent of assessment. Kattan et al.'s recent work incorporating IL6SRand TGFB into the preoperative nomogram for PSA recurrence after radicalprostatectomy is the first to improve nomogram accuracy, to ˜80%, with anew biomarker rather than biopsy data or a variation of PSA measurement(Kattan M W, Shariat S F, Andrews B, et al. J Clin Oncol2003;21(19):3573-9). Glinsky et al. used gene expression profiling tostratify patients into risk groups for recurrence but does not reportprobability tables or nomograms based on this data (Glinsky G V,Glinskii A B, Stephenson A J, Hoffman R M, Gerald W L., J Clin Invest2004;113(6):913-23). It should be noted that another report that usedgene expression to predict outcome was a 5 gene model that includedPDGFRβ, the receptor for a gene that maps to one of our GEMCaPbiomarkers (Singh D, Febbo P G, Ross K, et al. Cancer Cell2002;1(2):203-9).

It has been our hypothesis that genome copy number profiles can be usedto assess risk of disease recurrence, metastasis, and for elucidation ofthe biological mechanisms of metastasis. To test our hypothesis, we haveemployed array comparative genomic hybridization (aCGH) to the analysisof multiple cohorts of prostate tumors. Array CGH is a powerful tool forbiomarker discovery and identification of genes involved in CaPprogression because it allows high resolution and quantitative detectionof copy number aberrations in tumor genomes (Pinkel D, Segraves R, SudarD, et al. Nat Genet 1998;20(2):207-11; Veltman J A, Fridlyand J, PejavarS, et al. Cancer Res 2003;63(11):2872-80; Snijders A M, Nowee M E,Fridlyand J, et al. Oncogene 2003;22(27):4281-6) that can be associatedwith clinical outcome (Wilhelm M, Veltman J A, Olshen A B, et al. CancerRes 2002;62(4):957-60). We have analyzed prostate tumors using aCGH from64 men at intermediate to high-risk of progression with up to 16 yearsclinical follow-up (Paris P L, Andaya A, Fridlyand J, et al. Hum MolGenet 2004;13(13):1303-13). Half of the patients progressedbiochemically (PSA) and half did not. Included amongst the tumors thatrecurred are 12 primary tumors confirmed to have later metastasized tobone. In an independent study, the genomes of 15 organ metastases wereanalyzed using aCGH. Copy number profiles from the 12 primary tumorsthat metastasized and 15 metastases were used to detect signatures ofmetastasis in primary tumors. These events occur as relatively rareevents in primary tumors but manifest as highly recurrent amplificationsand deletions in the metastases. BAC clones at 39 loci (˜2400 clonesevaluated) were required to detect the signatures of metastasis (Paris PL, Andaya A, Fridlyand J, et al. Hum Mol Genet 2004;13(13):1303-13). Wecall these loci the genomic evaluators of metastatic CaP (GEMCap). Thisgroup of 39 BAC clones may be useful in predicting primary tumors thatare poised for metastasis or have already seeded occult micrometastases.The ability of the 39 loci to predict postoperative recurrence wascompared to the predictive value of the Kattan nomogram. TABLE 3 GEMCaPand nomogram risk classification for 27 UCSF radical prostatectomycases. Time to % of biochemical being failure or GEMCaP diseasesecondary Tx Biochemical or % aberrant metastatic free in Gleason Marginor last PSA secondary Tx GEMCaP risk 5 yr Sample ID sum status (months)failure? loci prediction Kattan 1 6 negative 38 N 0% L 80/89% 2 6negative 38 N 6% L 87% 3 6 negative 26 N 11% L 89% 4 6 negative 19 N 9%L N/A 5 5 positive 36 N 5% L 77% 6 7 negative 35 N 19% L 79% 7 6negative 36 N 3% L N/A 8 6 positive 32 N 0% L 84% 9 6 negative 23 N 6% L91% 10 7 negative 31 N 11% L 80% 11 8 negative 30 N 20% L 82% 12 6negative 9 N 6% L 89% 13 9 negative 21 N 14% L 84% 14 9 negative 19 N 0%L 55% 15 9 positive 5 Y 29% H 64% 16 6 positive 10 Y 31% H 91% 17 9positive 25 Y 56% H 77% 18 7 negative 3 Y 25% H 70% 19 9 negative 4 Y24% H 76% 20 7 negative 16 Y 41% H 71% 21 7 positive 11 Y 22% H 73% 22 7positive 13 Y 8% L 35% 23 8 positive 1 Y 8% L 76% 24 9 positive 7 Y 9% L53% 25 9 negative 43 N 27% H 73% 26 7 negative 35 N 28% H 59% 27 9negative 7 N 31% H N/A

TABLE 4 Comparing GEMCaP and Kattan nomogram with biochemicalrecurrence. GEMCaP Kattan 80% Accuracy 78% 75% (+) 70% 64% PredictiveValue (−) 82% 90% Predictive ValueMethods

Patient Selection and Tissue Processing: aCGH was available for 27 UCSFradical prostatectomy patients that were selected based on Gleason gradefor a separate study. Ten 13 micron slices were cut for each case fromfresh frozen prostate tissue blocks. H & E's were performed on 5 micronslices representative of the beginning and the end of the cut section. Asingle pathologist (J.S.) outlined areas of greater than 80% tumor formicrodissection with a scalpel. DNA was extracted using a proteinase Kdigestion and the Promega Wizard Kit (Madison, Wis.) as per themanufacturer's instructions. Two phenol:chloroform extractions followedby an ethanol precipitation were performed after the Promega kit's finalelution step.

aCGH: The human version 2.0 BAC arrays were purchased from the UCSFArray Core. Each array consists of 2,460 BAC clones spotted intriplicate on chromium slides (Pinkel D, Segraves R, Sudar D, et al. NatGenet 1998;20(2):207-11). The resolution is approximately 1.4 Mb. Wefollowed our published hybridization protocol (Paris P L, Albertson D G,Alers J C, et al. Am J Pathol 2003;162(3):763-70).

aCGH Statistical Analysis: The tumor:reference fluorescence intensityratios were converted to the log2 domain and the replicate spots wereaveraged. The observed log2ratios were not included if there were fewerthan two replicate spots (out of 3) or if the standard deviation of thereplicates was greater than 0.2. Each array was normalized to have amedian log2ratio of 0. To identify the gained and lost clones inindividual samples, sample-specific thresholds were constructed. TheGEMCaP clones with log2ratios above or below +/− a tumor's thresholdwere considered gained or lost, respectively. An Excel Macro has beenwritten in our laboratory to determine the percentage of aberrant GEMCAPloci based on the inputted aCGH data and TBT for a given patient. Alltumors were analyzed with this Macro.

Methods of Analysis for GEMCaP and Nomograms: As a summary measure, ifmore than 20% of the GEMCaP loci were aberrant for an individualpatient, then this was defined as a high metastatic risk case. Patientswere also classified according to the Kattan preoperative nomogram((Kattan M W, Eastham J A, Stapleton A M, Wheeler T M, Scardino P T. JNatl Cancer Inst 1998;90(10):766-71),http://www.mskcc.org/mskcc/html/10088.cfm) which weights thepreoperative PSA, biopsy Gleason grade and clinical T stage into asummary predictive 5 year probability of remaining recurrence free.

Results

Preliminary GEMCaP Biomarker Evaluation

To evaluate the predictive strength of the GEMCaP loci we asked if wecould blindly sort in silico 27 primary prostate tumors into metastasisrisk groups (low, high) based solely on the copy number status of these39 markers. The twenty-seven radical prostatectomy cases consisted oflow, intermediate and high-grade tumors. Using the Gleasoncategorization suggested by Steinberg et al., 10 tumors were low-grade(Gleason Score≦6), 7 were intermediate grade (Gleason Score=7) and 10were high-grade (Gleason Score≦8) (Steinberg D M, Sauvageot J,Piantadosi S, Epstein J I. Am J Surg Pathol 1997;21(5):566-76).Follow-up data was available for all patients. The test set consisted of17 non-progressors (median follow-up=31 months) and 10 progressors. Aprogressor was defined as a patient with a PSA≧0.2 ng/ml on 2consecutive occasions following prostatectomy, and/or a second cancertreatment for evidence of metastases>6 months after surgery. A tumorwith 20% or less of the GEMCaP loci aberrant was classified as low-riskof metastasis, and greater than 20% was classified as high-risk ofmetastasis. The biomarker group alone could predict risk of recurrencewith an accuracy of 78% (21/27, Table 3).

Accuracy of GEMCaP Biomarkers and Nomograms

The Kattan nomogram was used to analyze the 27 UCSF patients for whomGEMCaP predictions had been performed. Both predictions were madeindependent of one another and in a blinded fashion as to outcomestatus. The results are shown in Table 3. There were cases where bothmethods (i.e. GEMCAP and nomogram) seemed comparable in predicting risk.For example, patient #5 was at low-risk of failure using the GEMCAPloci, however he was at moderate risk of recurrence according to thenomogram. To date, patient #5 has not experienced a recurrence after 3years of follow-up. Conversely, patient #22 who recurred followingsurgery was at high-risk according to the nomogram, but not the GEMCAPloci. This preliminary study shows that there are patients who couldbenefit from the apparent complementary nature of these two methods.

For this pilot sample with 60% of the patients remaining disease freefor the observed duration of this study, the accuracy of the compositeGEMCaP loci classification was 78% compared with 75% by applying theKattan nomogram to identify being at least 80% recurrence free at 5years (Table 4). The positive predictive values for detecting recurrencewere 70% and 64%, respectively. The negative predictive values forremaining recurrence-free were 82% and 90%, respectively. These resultssuggest a strong ability of the GEMCAP loci to accurately identifypatients at risk of recurrence.

Discussion

Our 78% accuracy in predicting recurrence with BAC-based biomarkerscompared to 75% with a nomogram is extremely encouraging. In 3 of the 6samples where the biomarker group did not accurately assess recurrence,each had positive surgical margins suggesting that these patients mayhave failed for reasons independent of genetics. For the remaining threesamples (Table 3: #25-#27), one has been followed for less than fouryears, one less than three years, and one less than a year. We suggestthat these types of patients could be considered candidates forimmediate adjuvant therapy or at minimum, more active surveillance(Zincke H, Lau W, Bergstralh E, Blute M L. J Urol 2001;166(6):2208-15).

GEMCaP is a good tool for prognosis prediction and treatment selectionfor prostate cancer patients. For example, in this preliminary test setthere were 3 negative margin cases (Table 3: #18-#20) who recurred. Thetraditional method of predicting disease course using a nomogrampredicts that these individuals have a fairly high probability of beingdisease free for five years (60-81%) following radical prostatectomy.However, our GEMCAP analysis predicted all three were at high-risk of apostoperative recurrence. It is noteworthy that the three recurrencesoccurred within 16 months of surgery suggesting that GEMCaP analysismight potentially be useful for identifying patients with geneticallyaggressive disease and therefore good candidates for immediate adjuvant,systemic therapy.

An advantage to this approach is that DNA is a stable molecule and aCGHis quantitative. Overall accuracy of nomograms ranges from 50-70% andthis might ultimately be increased by inclusion of the GEMCAP loci.Identification of patients at risk for progression will assistclinicians in tailoring appropriate follow-up schedules and adjuvanttherapy decisions.

It is understood that the examples and embodiments described herein arefor illustrative purposes only and that various modifications or changesin light thereof will be suggested to persons skilled in the art and areto be included within the spirit and purview of this application andscope of the appended claims. All publications, patents, and patentapplications cited herein are hereby incorporated by reference in theirentirety for all purposes.

1. A method of assessing the risk of post-prostatectomy reoccurrence of cancer in a individual, the method comprising, detecting in a tumor sample from the individual the quantity of a MEN1 polynucleotide, wherein an individual with a risk of post-prostatectomy reoccurrence of cancer has an increased number of genomic copies of MEN1 per cell or increased expression of a MEN1 mRNA than a normal individual.
 2. The method of claim 1, wherein the MEN1 polynucleotide is genomic DNA and an increased number of copies per cell of the genomic DNA is associated with a risk of post-prostatectomy reoccurrence of cancer.
 3. The method of claim 1, wherein the MEN1 polynucleotide is a MEN1 mRNA or cDNA thereof and increased expression of the polynucleotide is associated with a risk of post-prostatectomy reoccurrence of cancer.
 4. The method of claim 1, further comprising detecting the tumor sample a polynucleotide at at least one genomic location selected from the group consisting of 2qtel, 3q26.2, 3q26.32, 5p15.1, 7p22.3, 7q11.23, 7q11.22, 7q22.1, 7q31.31, 9q34.11, 11p15.5, 17q21.33, 17q25.3, 22q13.1, 4p13, 5q13.1, 5q14.3, 5q21.1, 5q21.2, 5q21.3, 5q23.1, 6q14.1, 6q21, 8p22, 8p21.2, 8p12, 10q23.31, 13q14.11, 13q14.13, 13q14.2, 13q14 and 16q23.1.
 5. A method for determining the risk of metastasis of cancer in an individual who has or had prostate cancer, the method comprising, detecting in a tumor sample from the individual the number of copies per cell of genomic DNA at at least one genomic location selected from the group consisting of 2qtel, 3q26.2, 3q26.32, 5p15.1, 7p22.3, 7q11.23, 7q11.22, 7q22.1, 7q31.31, 9q34.11, 11p15.5, 17q21.33, 17q25.3, 22q13.1, 4p13, 5q13.1, 5q14.3, 5q21.1, 5q21.2, 5q21.3, 5q23.1, 6q14.1, 6q21, 8p22, 8p21.2, 8p12, 10q23.31, 13q14.11, 13q14.13, 13q14.2, 13q14 and 16q23.1, wherein an increase in the number of copies per cell of DNA in genomic locations selected from the group consisting of 2qtel, 3q26.2, 3q26.32, 5p15.1, 7p22.3, 7q11.23, 7q11.22, 7q22.1, 7q31.31, 9q34.11, 11p15.5, 17q21.33, 17q25.3 and 22q13.1 and/or a decrease in the number of copies per cell of DNA in genomic locations selected from the group consisting of 4p13, 5q13.1, 5q14.3, 5q21.1, 5q21.2, 5q21.3, 5q23.1, 6q14.1, 6q21, 8p22, 8p21.2, 8p12, 10q23.31, 13q14.11, 13q14.13, 13q14.2, 13q14 and 16q23.1, compared to the number of copies per cell in non-cancer cells, indicates an increased risk of metastasis.
 6. The method of claim 5, comprising detecting the number of copies per cell at least two of the genomic locations.
 7. The method of claim 5, comprising detecting the number of copies per cell at least six of the genomic locations.
 8. The method of claim 5, comprising detecting the number of copies per cell at 2qtel, 3q26.2, 3q26.32, 5p15.1, 7p22.3, 7q11.23, 7q11.22, 7q22.1, 7q31.31, 9q34.11, 11p15.5, 17q21.33, 17q25.3, 22q13.1, 4p13, 5q13.1, 5q14.3, 5q21.1, 5q21.2, 5q21.3, 5q23.1, 6q14.1, 6q21, 8p22, 8p21.2, 8p12, 10q23.31, 13q14.11, 13q14.13, 13q14.2, 13q14 and 16q23.1.
 9. The method of claim 5, comprising detecting the number of copies of genomic DNA that hybridizes to at least one BAC selected from the group consisting of CTB-172I13, RP11-1146E5, RP11-114M1, RP1-97B16, RP11-88L18, RP11-23D23, CTC-329F6, RP1-117G9, RP11-96016, RP11-213E22, CTD-2041G23, RP11-1704, RP4-693L23, RP5-1071I14, RP11-46E14, RMC22P003, RP11-253O5, RP11-267K19, RP11-135F5, RP11-203J7, RP11-115L24, CTD-2079J2, RP11-73N22, RP11-217L13, RP11-28L24, RP11-47E20, RP11-182G2, RP11-76B12, RP11-232J22, CTD-2015D3, RP11-5713, RP11-129G17, RP11-14A4, CTD-2202J2, RP11-17I11, RP11-217H23, CTD-2173J2, RP1-269F22, and RP11-12H11.
 10. The method of claim 5, comprising detecting the number of copies of genomic DNA in a gene selected from the group consisting of EV11, PIK3CA, EIF3S9, ELN, AUTS2, VGF, Serpine1, PLOD3, AP1S1, CORTBP2, p57 (KIP2), NGFR, CBX4, CBX8, PDGFB, FER, TUBE1, LAMA4, BVES, POPDC3, TUSC3, DOCK5, BNIP3L, ADRA1, NRG1, LHFP, GTF2F2, RB1 and CHC1L.
 11. A method of determining the stage of a prostate cancer tumor, the method comprising, detecting in a tumor sample from the individual the quantity of a CSMD1 polynucleotide, wherein an individual with an advanced stage of prostate cancer has fewer genomic copies of CSMD1 per cell or reduced expression of a CSMD1 mRNA than a normal individual.
 12. The method of claim 11, wherein the CSMD1 polynucleotide is genomic DNA and a decreased number of copies per cell of the genomic DNA is associated with an advanced stage of prostate cancer.
 13. The method of claim 11, wherein the CSMD1 polynucleotide is a CSMD1 mRNA or cDNA thereof and decreased expression of the polynucleotide is associated with an advanced stage of prostate cancer.
 14. The method of claim 11, further comprising detecting the tumor sample a polynucleotide at at least one genomic location selected from the group consisting of 2qtel, 3q26.2, 3q26.32, 5p15.1, 7p22.3, 7q11.23, 7q11.22, 7q22.1, 7q31.31, 9q34.11, 11p15.5, 17q21.33, 17q25.3, 22q13.1, 4p13, 5q13.1, 5q14.3, 5q21.1, 5q21.2, 5q21.3, 5q23.1, 6q14.1, 6q21, 8p22, 8p21.2, 8p12, 10q23.31, 13q14.11, 13q14.13, 13q14.2, 13q14 and 16q23.1.
 15. A method of identifying an agent that inhibits prostate cancer proliferation or metastasis, the method comprising, contacting a plurality of agents to a cell expressing a polypeptide selected from the group consisting of the gene products listed in Table 2; selecting an agent that modulates expression or activity of the polypeptide; and determining whether the selected agent inhibits prostate cancer proliferation or metastasis, thereby identifying an agent that inhibits prostate cancer proliferation or metastasis.
 16. An agent selected according to claim
 15. 17. A method of treating prostate cancer or inhibiting metastasis of prostate cancer, the method comprising, administrating to an individual in need thereof an agent selected according to claim
 15. 